{"content":"<li class=\"n-box-item date-title\" data-end=\"1535601599\" data-start=\"1535515200\" data-txt=\"Monday, December 23, 2019\">Wednesday, August 29, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3386675\" data-ts=\"1535588961\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNOV\" target=\"_blank\">MNOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386675-medinova-up-9-after-hours-on-successful-mid-stage-study-of-ibudilast-in-ms\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MediNova up 9% after hours on successful mid-stage study of ibudilast in MS</a></h4><ul><li>Thinly traded MediNova (NASDAQ:<a href='https://seekingalpha.com/symbol/MNOV' title='MediciNova, Inc.'>MNOV</a>) is up&nbsp;<font color='green'>9%</font>&nbsp;after hours on light volume on the heels of the&nbsp;<a href=\"https://seekingalpha.com/pr/17257002-medicinova-announces-publication-results-sprint-ms-phase-2b-trial-mnminus-166-ibudilast\" target=\"_blank\">release of results</a> from a Phase 2 clinical trial evaluating MN-166 (ibudilast) in patients with progressive multiple sclerosis (progressive MS). The data were just <a href=\"https://www.nejm.org/doi/full/10.1056/NEJMoa1803583?query=featured_home\" target=\"_blank\">published </a>in the <em>New England Journal of Medicine.&nbsp;</em></li><li>Patients receiving oral ibudilast twice daily experienced statistically significantly less brain shrinkage compared to placebo as measured by MRI analysis. Specifically, the rate of change in the brain parenchymal fraction [ratio of brain parenchymal (functional tissue of the brain) volume to total brain volume] was significantly less in the treatment group versus control.</li><li>The company plans to advance ibudilast into Phase 3 development.</li></ul><div class=\"tiny-share-widget\" data-id=\"3386675\" data-linked=\"MediNova up 9% after hours on successful mid-stage study of ibudilast in MS\" data-tweet=\"$MNOV - MediNova up 9% after hours on successful mid-stage study of ibudilast in MS https://seekingalpha.com/news/3386675-medinova-up-9-after-hours-on-successful-mid-stage-study-of-ibudilast-in-ms?source=tweet\" data-url=\"https://seekingalpha.com/news/3386675-medinova-up-9-after-hours-on-successful-mid-stage-study-of-ibudilast-in-ms\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:29 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386673\" data-ts=\"1535587643\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRPX\" target=\"_blank\">TRPX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386673-therapix-bio-up-20-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Therapix Bio up 20% after hours</a></h4><ul><li>Thinly traded nano cap Therapix Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/TRPX' title='Therapix Biosciences'>TRPX</a>) is up<font color='green'> 20%</font>&nbsp;after hours on increased volume, adding to its&nbsp;<font color='green'>20%</font>&nbsp;move in the regular session.</li><li>No particular news accounts for the action although it filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1611746/000121390018010534/f424b2072018_therapixbio.htm\" target=\"_blank\">prospectus </a>for a $50M mixed shelf offering several weeks ago.</li></ul><div class=\"tiny-share-widget\" data-id=\"3386673\" data-linked=\"Therapix Bio up 20% after hours\" data-tweet=\"$TRPX - Therapix Bio up 20% after hours https://seekingalpha.com/news/3386673-therapix-bio-up-20-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3386673-therapix-bio-up-20-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386656\" data-ts=\"1535578560\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GES\" target=\"_blank\">GES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386656-after-hours-gainers-losers-08-29-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (08/29/2018)</a></h4><ul>     <li><strong>Top Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/GES' title='Guess? Inc.'>GES</a> <font color='green'>+10.9%</font>. <a href='https://seekingalpha.com/symbol/TLYS' title='Tilly&#39;s, Inc.'>TLYS</a> <font color='green'>+9.4%</font>. <a href='https://seekingalpha.com/symbol/SMTC' title='Semtech Corporation'>SMTC</a> <font color='green'>+8.4%</font>. <a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals'>ZYNE</a> <font color='green'>+3.2%</font>.</li>     <li><strong>Top Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/UEPS' title='Net 1 UEPS Technologies, Inc.'>UEPS</a>&nbsp;<font color='red'>-14.2%</font>. <a href='https://seekingalpha.com/symbol/ATAI' title='ATA Inc.'>ATAI</a>&nbsp;<font color='red'>-3.3%</font>. <a href='https://seekingalpha.com/symbol/AFMD' title='Affimed Therapeutics'>AFMD</a>&nbsp;<font color='red'>-2.4%</font>. <a href='https://seekingalpha.com/symbol/CRM' title='Salesforce.com, Inc.'>CRM</a>&nbsp;<font color='red'>-2.2%</font>. <a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a>&nbsp;<font color='red'>-1.8%.</font></li>  </ul><div class=\"tiny-share-widget\" data-id=\"3386656\" data-linked=\"After Hours Gainers / Losers (08/29/2018)\" data-tweet=\"$GES $GES $TLYS - After Hours Gainers / Losers (08/29/2018) https://seekingalpha.com/news/3386656-after-hours-gainers-losers-08-29-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3386656-after-hours-gainers-losers-08-29-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386635\" data-ts=\"1535574894\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SMTC\" target=\"_blank\">SMTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386635-semtechplus-5_9-on-q2-beats-in-line-guide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Semtech +5.9% on Q2 beats, in-line guide</a></h4><ul><li>        Semtech (NASDAQ:<a href='https://seekingalpha.com/symbol/SMTC' title='Semtech Corporation'>SMTC</a>) shares gain 5.9% on Q2 beats with revenue up 7% Y/Y. In-line Q3 guidance has EPS of $0.58 to $0.64 (consensus: $0.60) and non-GAAP gross margin of 61.2% to 62.2%.</li><li>               Earnings call is scheduled for 5 PM Eastern with a webcast available <a href=\"https://www.semtech.com/\" target=\"_blank\">here</a>.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17256953-semtech-announces-second-quarter-fiscal-year-2019-results\" target=\"_blank\">Press release</a>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386620-semtech-beats-0_01-beats-revenue\" target=\"_blank\">Semtech beats by $0.01, beats on revenue</a> (Aug. 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3386635\" data-linked=\"Semtech +5.9% on Q2 beats, in-line guide\" data-tweet=\"$SMTC - Semtech +5.9% on Q2 beats, in-line guide https://seekingalpha.com/news/3386635-semtechplus-5_9-on-q2-beats-in-line-guide?source=tweet\" data-url=\"https://seekingalpha.com/news/3386635-semtechplus-5_9-on-q2-beats-in-line-guide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:34 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386619\" data-ts=\"1535573944\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PVH\" target=\"_blank\">PVH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386619-phillips-van-heusen-beats-0_08-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Phillips-Van Heusen beats by $0.08, beats on revenue</a></h4><ul><li>Phillips-Van Heusen (NYSE:<a href='https://seekingalpha.com/symbol/PVH' title='PVH Corp.'>PVH</a>): Q2 Non-GAAP EPS of $2.18 <span style=\"color:green\">beats by $0.08</span>; GAAP EPS of $2.12.</li><li>Revenue of $2.33B (+12.6% Y/Y) <font color='green'>beats by $40M</font>.</li><li>Shares <font color='green'>+1.17%</font>.</li><li><a href='https://seekingalpha.com/pr/17256956-pvh-corp-reports-2018-second-quarter-revenue-eps-guidance-raises-full-year-outlook'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3386619\" data-linked=\"Phillips-Van Heusen beats by $0.08, beats on revenue\" data-tweet=\"$PVH - Phillips-Van Heusen beats by $0.08, beats on revenue https://seekingalpha.com/news/3386619-phillips-van-heusen-beats-0_08-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3386619-phillips-van-heusen-beats-0_08-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386617\" data-ts=\"1535573902\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GES\" target=\"_blank\">GES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386617-guess-beats-0_04-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Guess beats by $0.04, misses on revenue</a></h4><ul><li>Guess (NYSE:<a href='https://seekingalpha.com/symbol/GES' title='Guess? Inc.'>GES</a>): Q2 Non-GAAP EPS of $0.36 <span style=\"color:green\">beats by $0.04</span>; GAAP EPS of $0.31.</li><li>Revenue of $645.87M (+13.6% Y/Y) <font color='red'>misses by $4.74M</font>.</li><li>Shares <font color='green'>+2.3%</font>.</li><li><a href='https://seekingalpha.com/pr/17256954-guess-inc-reports-second-quarter-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3386617\" data-linked=\"Guess beats by $0.04, misses on revenue\" data-tweet=\"$GES - Guess beats by $0.04, misses on revenue https://seekingalpha.com/news/3386617-guess-beats-0_04-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3386617-guess-beats-0_04-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386605\" data-ts=\"1535573330\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLYS\" target=\"_blank\">TLYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386605-tillys-beats-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tilly&#39;s beats by $0.03, beats on revenue</a></h4><ul><li>Tilly's (NYSE:<a href='https://seekingalpha.com/symbol/TLYS' title='Tilly&#39;s, Inc.'>TLYS</a>): Q2 Non-GAAP EPS of $0.29 <span style=\"color:green\">beats by $0.03</span>; GAAP EPS of $0.33.</li><li>Revenue of $157.41M (+13.4% Y/Y) <font color='green'>beats by $2.11M</font>.</li><li>Shares <font color='green'>+6.56%</font>.</li><li><a href='https://seekingalpha.com/pr/17256916-tilly-s-inc-announces-fiscal-2018-second-quarter-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3386605\" data-linked=\"Tilly&#39;s beats by $0.03, beats on revenue\" data-tweet=\"$TLYS - Tilly&#39;s beats by $0.03, beats on revenue https://seekingalpha.com/news/3386605-tillys-beats-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3386605-tillys-beats-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386597\" data-ts=\"1535571869\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARDX\" target=\"_blank\">ARDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386597-ardelyx-up-2-on-publication-of-novel-mechanism-of-action-of-lead-drug-tenapanor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ardelyx up 2% on publication of novel mechanism of action of lead drug tenapanor</a></h4><ul><li>Ardelyx (<a href='https://seekingalpha.com/symbol/ARDX' title='Ardelyx'>ARDX</a> <font color='green'>+2.3%</font>) is up on below-average volume on the heels of a paper detailing the <a href=\"https://seekingalpha.com/pr/17256827-ardelyx-announces-science-translational-medicine-publication-detailing-tenapanors-unique\" target=\"_blank\">novel mechanism of action</a> of tenapanor, an inhibitor of a protein called sodium/hydrogen exchanger 3 (NHE3), in late-stage development for the treatment of hyperphosphatemia (excess levels of phosphate in the blood) in patients with end-stage renal disease who are on dialysis. The paper was just <a href=\"http://stm.sciencemag.org/content/10/456/eaam6474\" target=\"_blank\">published </a>in the journal <em>Science Translational Medicine</em>.</li><li>The company says current therapies for hyperphosphatemia are phosphate binders which do an inconsistent job reducing serum phosphorus and pose safety risks and tolerability issues.</li><li>Tenapanor reduces serum phosphate by inhibiting a protein that plays a key role in phosphate absorption in the gut via a pathway called passive paracellular flux which occurs between cells. Inhibiting NHE3 decreases the permeability to phosphate which reduces absorption. The mechanism of action appears to be specific to phosphate with no effect on other ions.</li></ul><div class=\"tiny-share-widget\" data-id=\"3386597\" data-linked=\"Ardelyx up 2% on publication of novel mechanism of action of lead drug tenapanor\" data-tweet=\"$ARDX - Ardelyx up 2% on publication of novel mechanism of action of lead drug tenapanor https://seekingalpha.com/news/3386597-ardelyx-up-2-on-publication-of-novel-mechanism-of-action-of-lead-drug-tenapanor?source=tweet\" data-url=\"https://seekingalpha.com/news/3386597-ardelyx-up-2-on-publication-of-novel-mechanism-of-action-of-lead-drug-tenapanor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386586\" data-ts=\"1535569606\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSFT\" target=\"_blank\">MSFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386586-microsoft-azure-now-nvidia-gpu-cloud-support\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microsoft Azure now has Nvidia GPU Cloud support</a></h4><ul><li>        Microsoft (NASDAQ:<a href='https://seekingalpha.com/symbol/MSFT' title='Microsoft Corporation'>MSFT</a>) Azure <a href=\"https://venturebeat.com/2018/08/29/microsoft-azure-now-supports-nvidia-gpu-cloud-for-deep-learning/\" target=\"_blank\">now supports</a> Nvidia&rsquo;s (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) GPU Cloud for deep learning model training and interference.</li><li>               Nvidia&rsquo;s GPU Cloud provides software containers to accelerate high-performance computing for researchers and developers. The container registry supports deep learning tools like TensorFlow, PyTorch, and Microsoft&rsquo;s Cognitive Toolkit.&nbsp;</li><li>               Launched early last year, the GPU Cloud is driven by Volta and the Tensor Core GPU architecture.&nbsp;</li><li>               Microsoft also announced the general availability of its Azure CycleCloud tool for managing HPC clusters in its cloud platform.&nbsp;</li><li>               Microsoft shares are&nbsp;<font color='green'>up 1.3%</font>&nbsp;to $111.64.&nbsp;</li><li>               Nvidia shares are&nbsp;<font color='green'>up 1.9%</font>&nbsp;to $279.33.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3386586\" data-linked=\"Microsoft Azure now has Nvidia GPU Cloud support\" data-tweet=\"$MSFT $MSFT $NVDA - Microsoft Azure now has Nvidia GPU Cloud support https://seekingalpha.com/news/3386586-microsoft-azure-now-nvidia-gpu-cloud-support?source=tweet\" data-url=\"https://seekingalpha.com/news/3386586-microsoft-azure-now-nvidia-gpu-cloud-support\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386583\" data-ts=\"1535569018\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPAS\" target=\"_blank\">IPAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386583-technology-top-5-gainers-losers-of-2_55-pm-08-29-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 2.55 PM (08/29/2018)</a></h4><ul>     <li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/IPAS' title='IPASS INC'>IPAS</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/JG' title='Aurora Mobile'>JG</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/JMU' title='JMU Limited'>JMU</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/IZEA' title='IZEA Worldwide, Inc.'>IZEA</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/UAVS' title='AgEagle'>UAVS</a> <font color='green'>+11%</font>.</li>     <li><strong>Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/OSS' title='One Stop Systems, Inc.'>OSS</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/SCSC' title='ScanSource, Inc.'>SCSC</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/BOX' title='Box'>BOX</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/ARLO' title='Arlo Technologies'>ARLO</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/MOXC' title='Moxian, Inc.'>MOXC</a> <font color='red'>-7%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3386583\" data-linked=\"Technology - Top 5 Gainers / Losers as of 2.55 PM (08/29/2018)\" data-tweet=\"$IPAS $IPAS $JG - Technology - Top 5 Gainers / Losers as of 2.55 PM (08/29/2018) https://seekingalpha.com/news/3386583-technology-top-5-gainers-losers-of-2_55-pm-08-29-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3386583-technology-top-5-gainers-losers-of-2_55-pm-08-29-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386571\" data-ts=\"1535565665\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IGC\" target=\"_blank\">IGC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386571-energy-materials-top-gainers-losers-of-2-00-pm-08-29-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 PM (08/29/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a> <font color='green'>+42%</font>. <a href='https://seekingalpha.com/symbol/CRC' title='California Resources Corporation'>CRC</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/MVO' title='MV Oil Trust'>MVO</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/ACET' title='Aceto Corporation'>ACET</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/PED' title='PEDEVCO Corp.'>PED</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/METC' title='Ramaco'>METC</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/LAC' title='Lithium Americas Corp.'>LAC</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3386571\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 PM (08/29/2018)\" data-tweet=\"$IGC $IGC $CRC - Energy/Materials - Top Gainers / Losers as of 2:00 PM (08/29/2018) https://seekingalpha.com/news/3386571-energy-materials-top-gainers-losers-of-2-00-pm-08-29-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3386571-energy-materials-top-gainers-losers-of-2-00-pm-08-29-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386569\" data-ts=\"1535565085\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLRY\" target=\"_blank\">TLRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386569-trumps-secret-war-on-weed-buzzfeed\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trump&#39;s secret war on weed - BuzzFeed</a></h4><ul><li>The administration's&nbsp;Marijuana Policy Coordination Committee is aiming to combat public support for marijuana and throw a negative spin on state legalization initiatives, writes Dominic Holden.</li><li>\"The prevailing marijuana narrative in the U.S. is partial, one-sided, and inaccurate,&rdquo; says a summary of a recent meeting between the White House and nine federal agencies.</li><li><a href=\"https://www.buzzfeednews.com/article/dominicholden/trump-secret-committee-anti-marijuana\" target=\"_blank\">Full report here</a></li><li>For now, most names are ignoring, including red-hot Tilray (<a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a> <font color='green'>+15%</font>), Canopy Growth (<a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a> <font color='green'>+3.9%</font>), and Cronos Group (<a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group, Inc.'>CRON</a> <font color='green'>+10.1%</font>).</li><li>Related names: <a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a>, <a href='https://seekingalpha.com/symbol/MJNA' title='Medical Marijuana, Inc.'>OTCPK:MJNA</a>, ACBFF, <a href='https://seekingalpha.com/symbol/GWPH' title='GW Pharmaceuticals plc'>GWPH</a>, <a href='https://seekingalpha.com/symbol/PHOT' title='Growlife Inc.'>OTCQB:PHOT</a>, <a href='https://seekingalpha.com/symbol/CBIS' title='Cannabis Science, Inc.'>OTCPK:CBIS</a>, APHQF, <a href='https://seekingalpha.com/symbol/TRTC' title='Terra Tech Corp.'>OTCQX:TRTC</a>, <a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group, Inc.'>CRON</a>, <a href='https://seekingalpha.com/symbol/CANN' title='General Cannabis Corp.'>OTCQX:CANN</a>, <a href='https://seekingalpha.com/symbol/ERBB' title='American Green, Inc.'>OTCPK:ERBB</a>, <a href='https://seekingalpha.com/symbol/GRNH' title='GreenGro Technologies, Inc.'>OTCPK:GRNH</a>, <a href='https://seekingalpha.com/symbol/PMCB' title='PharmaCyte Biotech, Inc.'>OTCQB:PMCB</a>, <a href='https://seekingalpha.com/symbol/CVSI' title='CV Sciences, Inc.'>OTCQB:CVSI</a>, <a href='https://seekingalpha.com/symbol/FITX' title='Creative Edge Nutrition, Inc.'>OTC:FITX</a>, <a href='https://seekingalpha.com/symbol/MJ' title='ETFMG Alternative Harvest ETF'>MJ</a>, <a href='https://seekingalpha.com/symbol/HEMP' title='Hemp, Inc.'>OTCPK:HEMP</a>, <a href='https://seekingalpha.com/symbol/CBDS' title='Cannabis Sativa, Inc.'>OTCQB:CBDS</a>, <a href='https://seekingalpha.com/symbol/BLOZF' title='Cannabix Technologies Inc.'>OTCPK:BLOZF</a>, <a href='https://seekingalpha.com/symbol/KSHB' title='KushCo Holdings, Inc.'>OTCQB:KSHB</a>, <a href='https://seekingalpha.com/symbol/MSRT' title='MassRoots, Inc.'>OTCQB:MSRT</a>, <a href='https://seekingalpha.com/symbol/SPRWF' title='Supreme Cannabis Co Inc.'>OTCQX:SPRWF</a>, <a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a>, <a href='https://seekingalpha.com/symbol/AGTK' title='Agritek Holdings, Inc.'>OTCPK:AGTK</a>, <a href='https://seekingalpha.com/symbol/AMMJ' title='American Cannabis Company, Inc.'>OTCPK:AMMJ</a>, <a href='https://seekingalpha.com/symbol/VAPE' title='Vape Holdings, Inc.'>OTCPK:VAPE</a>, HYYDF, <a href='https://seekingalpha.com/symbol/GBLX' title='GB Sciences, Inc.'>OTCQB:GBLX</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3386569\" data-linked=\"Trump&#39;s secret war on weed - BuzzFeed\" data-tweet=\"$TLRY $TLRY $CGC - Trump&#39;s secret war on weed - BuzzFeed https://seekingalpha.com/news/3386569-trumps-secret-war-on-weed-buzzfeed?source=tweet\" data-url=\"https://seekingalpha.com/news/3386569-trumps-secret-war-on-weed-buzzfeed\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>245&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386566\" data-ts=\"1535564660\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVSI\" target=\"_blank\">CVSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386566-cv-sciences-down-another-24-citron-covers-short\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CV Sciences down another 24%; Citron covers short</a></h4><ul><li>\"Making 70% in a week is always a good trade,\" <a href=\"https://twitter.com/CitronResearch/status/1034849283982286848\" target=\"_blank\">tweets Andrew Left</a>. \"Stay tuned for more cannabis trades.\"</li><li><a href='https://seekingalpha.com/symbol/CVSI' title='CV Sciences, Inc.'>OTCQB:CVSI</a>&nbsp;<font color='red'>-24.1%</font>&nbsp;to $3.15 today.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3384255-cv-sciences-26-percent-bearish-citron-report\" target=\"_blank\">CV Sciences down 26% on bearish Citron report</a> (Aug. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3386566\" data-linked=\"CV Sciences down another 24%; Citron covers short\" data-tweet=\"$CVSI - CV Sciences down another 24%; Citron covers short https://seekingalpha.com/news/3386566-cv-sciences-down-another-24-citron-covers-short?source=tweet\" data-url=\"https://seekingalpha.com/news/3386566-cv-sciences-down-another-24-citron-covers-short\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386564\" data-ts=\"1535563803\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386564-micron-plans-3b-expansion-for-virginia-chip-plant\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron plans $3B expansion for Virginia chip plant</a></h4><ul><li>        Micron (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>) <a href=\"https://seekingalpha.com/pr/17256770-micron-announces-investment-semiconductor-manufacturing-plant-manassas-virginia\" target=\"_blank\">will spend $3B</a> to expand its chip plant in Manassas, Virginia.</li><li>The initial expansion will complete in the fall of next year with production starting in 1H20.&nbsp;</li><li>        The significant project will create 1,100 jobs by 2030.</li><li>               Micron also plans to set up an R&amp;D center in Manassas primarily focusing on memory and storage for the auto and industrial markets. The center will employ around 100 engineers.&nbsp;</li><li>               Micron shares are&nbsp;<font color='red'>down 0.9%</font>&nbsp;to $51.87.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3386564\" data-linked=\"Micron plans $3B expansion for Virginia chip plant\" data-tweet=\"$MU - Micron plans $3B expansion for Virginia chip plant https://seekingalpha.com/news/3386564-micron-plans-3b-expansion-for-virginia-chip-plant?source=tweet\" data-url=\"https://seekingalpha.com/news/3386564-micron-plans-3b-expansion-for-virginia-chip-plant\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>214&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386561\" data-ts=\"1535563099\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYNA\" target=\"_blank\">SYNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386561-synapticsplus-5_4-on-checks-showing-profitable-market-shift\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synaptics +5.4% on checks showing profitable market shift</a></h4><ul><li>        Craig-Hallum analyst Anthony Stoss says checks indicate that Synaptics (NASDAQ:<a href='https://seekingalpha.com/symbol/SYNA' title='Synaptics Incorporated'>SYNA</a>) customers are changing up 2019 designs from chip-on-glass &#40;COG&#41; to LCD chip-on-flex &#40;COF&#41;, which is a more expensive solution.</li><li>                  The firm thinks COF will quickly take 50% to 60% share of the handset market.    </li><li>               Firm maintains a Buy rating and $56 price target.&nbsp;</li><li>               Source: StreetAccount.&nbsp;</li><li>               Synaptics shares are<font color='green'> up 5.4%</font>&nbsp;to $48.43.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3386561\" data-linked=\"Synaptics +5.4% on checks showing profitable market shift\" data-tweet=\"$SYNA - Synaptics +5.4% on checks showing profitable market shift https://seekingalpha.com/news/3386561-synapticsplus-5_4-on-checks-showing-profitable-market-shift?source=tweet\" data-url=\"https://seekingalpha.com/news/3386561-synapticsplus-5_4-on-checks-showing-profitable-market-shift\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:18 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386555\" data-ts=\"1535562063\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YRD\" target=\"_blank\">YRD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386555-financials-top-gainers-losers-of-1-00-pm-08-29-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top Gainers / Losers as of 1:00 PM (08/29/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/YRD' title='Yirendai LTD.'>YRD</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/MFIN' title='Medallion Financial'>MFIN</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/PPDF' title='PPDAI Group Inc.'>PPDF</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/KFS' title='Kingsway Financial Services Inc'>KFS</a> <font color='red'>-13%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3386555\" data-linked=\"Financials - Top Gainers / Losers as of 1:00 PM (08/29/2018)\" data-tweet=\"$YRD $YRD $MFIN - Financials - Top Gainers / Losers as of 1:00 PM (08/29/2018) https://seekingalpha.com/news/3386555-financials-top-gainers-losers-of-1-00-pm-08-29-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3386555-financials-top-gainers-losers-of-1-00-pm-08-29-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386552\" data-ts=\"1535561648\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOSL\" target=\"_blank\">FOSL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386552-fossil-follows-movado-lower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fossil follows Movado lower</a></h4><ul><li>Shares of Fossil (NASDAQ:<a href='https://seekingalpha.com/symbol/FOSL' title='Fossil, Inc.'>FOSL</a>) are&nbsp;<font color='red'>down 8.2%</font>&nbsp;after Movado sets guidance below expectations.</li><li>Fossil is cooling off today from what has been a monster +175% YTD run.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386503-movado-minus-12-percent-outlook-disappoints\" target=\"_blank\">Movado -12% after outlook disappoints</a> (Aug. 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3386552\" data-linked=\"Fossil follows Movado lower\" data-tweet=\"$FOSL - Fossil follows Movado lower https://seekingalpha.com/news/3386552-fossil-follows-movado-lower?source=tweet\" data-url=\"https://seekingalpha.com/news/3386552-fossil-follows-movado-lower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:54 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386551\" data-ts=\"1535561632\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GKOS\" target=\"_blank\">GKOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386551-jpmorgan-bullish-on-glaukos-after-alcon-stent-exit-sees-24-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan bullish on Glaukos after Alcon stent exit; sees 24% upside</a></h4><ul><li>JPMorgan analyst Robbie Marcus has hitched a ride on Glaukos (<a href='https://seekingalpha.com/symbol/GKOS' title='Glaukos'>GKOS</a> <font color='green'>+34.9%</font>) after Novartis' Alcon unit <a href=\"https://seekingalpha.com/news/3386400-glaukos-18-percent-premarket-alcon-voluntary-withdrawal-rival-eye-stent\" target=\"_blank\">announced </a>plans to withdraw its CyPass MIcro-Stent from the U.S. market. The device is indicated for reducing intraocular pressure in glaucoma patients.</li><li>Mr. Marcus says Alcon's move bodes well for Glaukos' iStent. He has upgraded the stock to Overweight with a $75 (24% upside) price target.</li></ul><div class=\"tiny-share-widget\" data-id=\"3386551\" data-linked=\"JPMorgan bullish on Glaukos after Alcon stent exit; sees 24% upside\" data-tweet=\"$GKOS - JPMorgan bullish on Glaukos after Alcon stent exit; sees 24% upside https://seekingalpha.com/news/3386551-jpmorgan-bullish-on-glaukos-after-alcon-stent-exit-sees-24-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3386551-jpmorgan-bullish-on-glaukos-after-alcon-stent-exit-sees-24-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386550\" data-ts=\"1535561299\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPNT\" target=\"_blank\">OPNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386550-midday-gainers-losers-08-29-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (08/29/2018)</a></h4><ul>     <li><strong>Gainers:</strong> <a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a> <font color='green'>+50%</font>. <a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a> <font color='green'>+40%</font>. <a href='https://seekingalpha.com/symbol/GKOS' title='Glaukos'>GKOS</a> <font color='green'>+36%</font>. <a href='https://seekingalpha.com/symbol/EVFM' title='Evofem Biosciences, Inc.'>EVFM</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/IPAS' title='IPASS INC'>IPAS</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/SPHS' title='Sophiris Bio'>SPHS</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/AFMD' title='Affimed Therapeutics'>AFMD</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/JMU' title='JMU Limited'>JMU</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/YRD' title='Yirendai LTD.'>YRD</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals'>ZYNE</a> <font color='green'>+17%</font>.</li>     <li><strong>Losers:</strong> <a href='https://seekingalpha.com/symbol/MOV' title='Movado Group, Inc.'>MOV</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/ASRT' title='Assertio Therapeutics Inc'>ASRT</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/STAF' title='Staffing 360 Solutions, Inc.'>STAF</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/AGMH' title='AGM Group Holdings Inc.'>AGMH</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/TPNL' title='3Pea International, Inc.'>TPNL</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/SCSC' title='ScanSource, Inc.'>SCSC</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/ZLAB' title='Zai Lab Ltd.'>ZLAB</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/ATAI' title='ATA Inc.'>ATAI</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/FOSL' title='Fossil, Inc.'>FOSL</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/BOX' title='Box'>BOX</a> <font color='red'>-8%</font>.</li> &nbsp;     &nbsp; </ul><div class=\"tiny-share-widget\" data-id=\"3386550\" data-linked=\"Midday Gainers / Losers (08/29/2018)\" data-tweet=\"$OPNT $OPNT $IGC - Midday Gainers / Losers (08/29/2018) https://seekingalpha.com/news/3386550-midday-gainers-losers-08-29-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3386550-midday-gainers-losers-08-29-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386547\" data-ts=\"1535560712\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KEQU\" target=\"_blank\">KEQU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386547-kewaunee-scientific-down-7-post-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kewaunee Scientific down 7% post Q1 results</a></h4><ul><li>Kewaunee Scientific (<a href='https://seekingalpha.com/symbol/KEQU' title='Kewaunee Scientific Corporation'>KEQU</a> <font color='red'>-7.9%</font>) reported Q1 sales of $42.15M an increase of 24.4% Y/Y, with Domestic sales of $36.07M (+63% Y/Y) and International sales of $6.08M (-48% Y/Y).</li><li>Domestic sales increased due to strong demand for laboratory, healthcare, and technical furniture products. International sales declined as a large order partially delivered in 1Q18 was not repeated for 1Q19.</li><li>Q1 Overall gross margin&nbsp;<font color='red'>declined by 240 bps</font>&nbsp;to 17.7% and operating margin&nbsp;<font color='red'>declined by 92 bps&nbsp;</font>to 4.06%.</li><li>Inventories were at $15M a decrease of 15.04% Y/Y.</li><li>Backlog was $102.1M as of July 31, 2018, compared to $111.2M a year ago.</li><li>Company has cash and cash equivalents of $9.06M as of July 31, 2018.</li><li>Company's debt-to-equity ratio at July 31, 2018 was .20-to-1, as compared to .15-to-1 a year ago.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386328-kewaunee-scientific-misses-0_01-beats-revenue\" target=\"_blank\">Kewaunee Scientific misses by $0.01, beats on revenue</a> (Aug. 28)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386504-kewaunee-scientific-declares-0_19-dividend\" target=\"_blank\">Kewaunee Scientific declares $0.19 dividend</a> (Aug. 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3386547\" data-linked=\"Kewaunee Scientific down 7% post Q1 results\" data-tweet=\"$KEQU - Kewaunee Scientific down 7% post Q1 results https://seekingalpha.com/news/3386547-kewaunee-scientific-down-7-post-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3386547-kewaunee-scientific-down-7-post-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386546\" data-ts=\"1535560160\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MGM\" target=\"_blank\">MGM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386546-mgm-resorts-higher-amid-activist-chatter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MGM Resorts higher amid activist chatter</a></h4><ul><li>MGM Resorts (NYSE:<a href='https://seekingalpha.com/symbol/MGM' title='MGM Resorts International'>MGM</a>) is&nbsp;<font color='green'>up 2.4%</font>&nbsp;after The Deal says activist investors are \"agitating\" again over the company's track.</li><li>Investment manager Land and Buildings is one of the more notable former vocal critics of the casino operator.</li></ul><div class=\"tiny-share-widget\" data-id=\"3386546\" data-linked=\"MGM Resorts higher amid activist chatter\" data-tweet=\"$MGM - MGM Resorts higher amid activist chatter https://seekingalpha.com/news/3386546-mgm-resorts-higher-amid-activist-chatter?source=tweet\" data-url=\"https://seekingalpha.com/news/3386546-mgm-resorts-higher-amid-activist-chatter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386543\" data-ts=\"1535559586\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAOI\" target=\"_blank\">AAOI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386543-applied-optoelectronics-ceo-general-counsel-pick-up-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Applied Optoelectronics CEO, general counsel pick up more shares</a></h4><ul><li>        Applied Optoelectronics (NASDAQ:<a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a>) CEO Chih-Hsiang Lin <a href=\"https://seekingalpha.com/filing/4151956\" target=\"_blank\">acquires</a> 40,000 shares at an average price of $9.96/share. Lin disposes of 21,378 shares at $42.87/share as a &ldquo;net exercise&rdquo; of outstanding stock options.&nbsp; Beneficial ownership now totals about 677.5K.</li><li>               General counsel David Kuo <a href=\"https://seekingalpha.com/filing/4151968\" target=\"_blank\">acquires</a> 506 shares are an average price of $9.96/share and 300 at $13.84/share. The purchases brought Kuo&rsquo;s beneficial ownership up to 30,452 shares.&nbsp;</li><li>               AAOI shares are&nbsp;<font color='green'>up 0.7%</font>&nbsp;to $43.05.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3386543\" data-linked=\"Applied Optoelectronics CEO, general counsel pick up more shares\" data-tweet=\"$AAOI - Applied Optoelectronics CEO, general counsel pick up more shares https://seekingalpha.com/news/3386543-applied-optoelectronics-ceo-general-counsel-pick-up-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3386543-applied-optoelectronics-ceo-general-counsel-pick-up-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386541\" data-ts=\"1535559432\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386541-oils-advance-boosts-energy-sector\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oil&#39;s advance boosts energy sector</a></h4><ul><li>WTI crude oil is&nbsp;<font color='green'>up 1.15%</font>&nbsp;to $69.32 after the EIA reported a larger-than-expected decline in domestic inventories.</li><li>That's providing a lift to the energy stocks, with the <a href='https://seekingalpha.com/symbol/XLE' title='Energy Select Sector SPDR ETF'>XLE</a>'s&nbsp;<font color='green'>0.85% gain&nbsp;</font>outpacing the S&amp;P 500's&nbsp;<font color='green'>0.6% move</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLE' title='Energy Select Sector SPDR ETF'>XLE</a>, <a href='https://seekingalpha.com/symbol/VDE' title='Vanguard Energy ETF'>VDE</a>, <a href='https://seekingalpha.com/symbol/ERX' title='Direxion Daily Energy Bull 3x Shares ETF'>ERX</a>, <a href='https://seekingalpha.com/symbol/OIH' title='VanEck Vectors Oil Services ETF'>OIH</a>, <a href='https://seekingalpha.com/symbol/ERY' title='Direxion Daily Energy Bear 3x Shares ETF'>ERY</a>, <a href='https://seekingalpha.com/symbol/DIG' title='ProShares Ultra Oil & Gas ETF'>DIG</a>, <a href='https://seekingalpha.com/symbol/BGR' title='BlackRock Energy&Resources Trust'>BGR</a>, <a href='https://seekingalpha.com/symbol/FENY' title='Fidelity MSCI Energy Index ETF'>FENY</a>, <a href='https://seekingalpha.com/symbol/IYE' title='iShares U.S. Energy ETF'>IYE</a>, <a href='https://seekingalpha.com/symbol/DUG' title='ProShares UltraShort Oil & Gas ETF'>DUG</a>, <a href='https://seekingalpha.com/symbol/FIF' title='First Trust Energy Infrastructure Fund'>FIF</a>, <a href='https://seekingalpha.com/symbol/RYE' title='Invesco S&P Equal Weight Energy ETF'>RYE</a>, <a href='https://seekingalpha.com/symbol/PXJ' title='Invesco Dynamic Oil & Gas Services Portfolio ETF'>PXJ</a>, <a href='https://seekingalpha.com/symbol/CRAK' title='VanEck Vectors Oil Refiners ETF'>CRAK</a>, <a href='https://seekingalpha.com/symbol/FXN' title='First Trust Energy AlphaDEX ETF'>FXN</a>, <a href='https://seekingalpha.com/symbol/DDG' title='ProShares Short Oil & Gas ETF'>DDG</a>, <a href='https://seekingalpha.com/symbol/NANR' title='SPDR S&P North American Natural Resources ETF'>NANR</a>, <a href='https://seekingalpha.com/symbol/FTXN' title='First Trust Nasdaq Oil & Gas ETF'>FTXN</a>, <a href='https://seekingalpha.com/symbol/JHME' title='John Hancock Multifactor Energy ETF'>JHME</a>, <a href='https://seekingalpha.com/symbol/ERYY' title='Direxion Daily Energy Bear 1x Shares ETF'>ERYY</a>, <a href='https://seekingalpha.com/symbol/ERGF' title='iShares Edge MSCI Multifactor Energy ETF'>ERGF</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3386541\" data-linked=\"Oil&#39;s advance boosts energy sector\" data-tweet=\"$XLE $VDE $ERX - Oil&#39;s advance boosts energy sector https://seekingalpha.com/news/3386541-oils-advance-boosts-energy-sector?source=tweet\" data-url=\"https://seekingalpha.com/news/3386541-oils-advance-boosts-energy-sector\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386539\" data-ts=\"1535559094\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IRMD\" target=\"_blank\">IRMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386539-profit-taking-pressures-iradimed-down-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Profit-taking pressures iRadimed, down 8%</a></h4><ul><li>Thinly traded micro cap iRadimed (<a href='https://seekingalpha.com/symbol/IRMD' title='iRadimed Corp.'>IRMD</a> <font color='red'>-8.1%</font>) is down on more than double normal volume. Shares have retraced almost&nbsp;<font color='red'>15%</font>&nbsp;since touching $29.95 yesterday as investors bag profits from its&nbsp;<font color='green'>130%</font>&nbsp;run-up since early March.</li><li>The company markets an MRI infusion pump and MRI pulse oximeter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3386539\" data-linked=\"Profit-taking pressures iRadimed, down 8%\" data-tweet=\"$IRMD - Profit-taking pressures iRadimed, down 8% https://seekingalpha.com/news/3386539-profit-taking-pressures-iradimed-down-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3386539-profit-taking-pressures-iradimed-down-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386538\" data-ts=\"1535558478\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WPRT\" target=\"_blank\">WPRT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386538-consumer-top-gainers-losers-of-12-00-pm-08-29-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 PM (08/29/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/WPRT' title='Westport Fuel Systems, Inc.'>WPRT</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/SEED' title='Origin Agritech Limited'>SEED</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/MOV' title='Movado Group, Inc.'>MOV</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/FOSL' title='Fossil, Inc.'>FOSL</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/TOUR' title='Tuniu Corporation'>TOUR</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/NAKD' title='Naked Brand Group Limited'>NAKD</a> <font color='red'>-5%</font>. AOI <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3386538\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 PM (08/29/2018)\" data-tweet=\"$WPRT $WPRT $SEED - Consumer - Top Gainers / Losers as of 12:00 PM (08/29/2018) https://seekingalpha.com/news/3386538-consumer-top-gainers-losers-of-12-00-pm-08-29-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3386538-consumer-top-gainers-losers-of-12-00-pm-08-29-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386535\" data-ts=\"1535558206\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORGS\" target=\"_blank\">ORGS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386535-orgenesis-continues-slide-down-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Orgenesis continues slide, down 8%</a></h4><ul><li>Thinly traded nano cap Orgenesis (<a href='https://seekingalpha.com/symbol/ORGS' title='Orgenesis, Inc.'>ORGS</a> <font color='red'>-7.8%</font>) is down on almost triple normal volume, albeit on turnover of only 74K shares. The stock has sold off nearly&nbsp;<font color='red'>20%</font>&nbsp;since <a href=\"https://seekingalpha.com/pr/17252000-orgenesis-announces-collaboration-ben-gurion-university-develop-commercialize-novel-scaffold\" target=\"_blank\">announcing </a>a collaboration last week with Ben-Gurion University to develop and commercialize a new scaffold technology for cell transplantation.</li><li>At the end of May, the company had $4.5M in cash and equivalents while operations consumed $6.9M over the previous two fiscal quarters. In March, it <a href=\"https://seekingalpha.com/news/3340358-orgenesis-registers-100m-mixed-shelf-offering\" target=\"_blank\">filed </a>for a $100M mixed shelf offering.</li></ul><div class=\"tiny-share-widget\" data-id=\"3386535\" data-linked=\"Orgenesis continues slide, down 8%\" data-tweet=\"$ORGS - Orgenesis continues slide, down 8% https://seekingalpha.com/news/3386535-orgenesis-continues-slide-down-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3386535-orgenesis-continues-slide-down-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386533\" data-ts=\"1535557770\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EVLV\" target=\"_blank\">EVLV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386533-evine-live-up-2_3-post-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EVINE Live up 2.3% post Q2 results</a></h4><ul><li>EVINE Live Inc (<a href='https://seekingalpha.com/symbol/EVLV' title='EVINE Live Inc.'>EVLV</a> <font color='green'>+2.3%</font>) <a href=\"https://seekingalpha.com/pr/17255971-evine-live-inc-reports-second-quarter-2018-results\" target=\"_blank\">reports Q2</a> revenue growth of 1.2% Y/Y to $150.8M.</li><li>Gross profit margin&nbsp;<font color='red'>declined 20 bps</font>&nbsp;to 37.7%.</li><li>Adj. EBITDA of $3.9M increased 12% Y/Y.</li><li>Operating expenses decreased 1.7% Y/Y to $56M, reflecting reduced variable selling and distribution expenses.</li><li>Net shipped units were 2,462 (+2% Y/Y) &amp; Average Selling Price was $55.</li><li>The return rate for the quarter was 18.7%; an&nbsp;<font color='green'>improvement of 40 bps</font>&nbsp;Y/Y and across multiple categories.</li><li>Total customers-12 month rolling were 1,255 (-9% Y/Y).</li><li>Introduced 17 new brands during Q2.</li><li>Total unrestricted cash was $28.1M &amp; the Company total liquidity was $51.4M.</li><li>The company strengthened the balance sheet and overall liquidity with an amendment of credit facility.</li><li><strong>2018 Outlook:</strong> Sales growth 2%-5%; Adj. EBITDA to be $19-21M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386358-evine-live-beats-0_02-beats-revenue\" target=\"_blank\">EVINE Live beats by $0.02, beats on revenue</a> (Aug. 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3386533\" data-linked=\"EVINE Live up 2.3% post Q2 results\" data-tweet=\"$EVLV $IMBI - EVINE Live up 2.3% post Q2 results https://seekingalpha.com/news/3386533-evine-live-up-2_3-post-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3386533-evine-live-up-2_3-post-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386528\" data-ts=\"1535557367\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XPLT\" target=\"_blank\">XPLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386528-xpel-technologies-jumps-17-after-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xpel Technologies jumps 17% after Q2 results</a></h4><ul><li>Xpel Technologies (<a href='https://seekingalpha.com/symbol/XPLT' title='Xpel Technologies Corp.'>OTC:XPLT</a> <font color='green'>+17.3%</font>) reported Q2 revenue growth of 69.3% Y/Y and 14.7% Q/Q to $28.9M.</li><li>Q2 Gross margin&nbsp;<font color='green'>improved by 270 bps</font>&nbsp;to 29.8%, due to price increases across certain product lines and operating margin&nbsp;<font color='green'>improved by 456 bps</font>&nbsp;to 11.9%.</li><li>EBITDA increased by 128.6% Y/Y to $3.84M and margin&nbsp;<font color='green'>improved by 345 bps&nbsp;</font>to 13.3%.</li><li>SG&amp;A expenses were $5.17M up by 53.4% Y/Y and as percentage of sale 17.9% down by 186 bps.</li><li>Company has Cash and cash equivalent of $1.53M as of June 30, 2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386444-xpel-technologies-reports-q2-results\" target=\"_blank\">Xpel Technologies reports Q2 results</a> (Aug. 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3386528\" data-linked=\"Xpel Technologies jumps 17% after Q2 results\" data-tweet=\"$XPLT $XPEL - Xpel Technologies jumps 17% after Q2 results https://seekingalpha.com/news/3386528-xpel-technologies-jumps-17-after-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3386528-xpel-technologies-jumps-17-after-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386530\" data-ts=\"1535557330\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EVFM\" target=\"_blank\">EVFM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386530-evofem-advancing-amphora-gel-for-prevention-of-certain-stds-in-women-shares-ahead-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Evofem advancing Amphora gel for prevention of certain STDs in women; shares ahead 15%</a></h4><ul><li>Thinly traded nano cap Evofem Biosciences (<a href='https://seekingalpha.com/symbol/EVFM' title='Evofem Biosciences, Inc.'>EVFM</a> <font color='green'>+14.5%</font>) is up on a 4x surge in volume, albeit on turnover of only 259K shares. The stock has rallied over&nbsp;<font color='green'>60%&nbsp;</font>since touching $1.83 on August 8.</li><li>This morning, it <a href=\"https://seekingalpha.com/pr/17256372-rise-prevalence-stds-reported-cdc-supports-continued-development-novel-solutions-like-evofems\" target=\"_blank\">announced </a>new CDC data that showed increasing rates of sexually transmitted diseases (STDs) in the U.S. Specifically, 2.3M cases were reported, up almost 10% in a year.</li><li>The company's lead candidate is <a href=\"http://www.evofem.com/products/\" target=\"_blank\">Amphora</a>, a vaginal gel in Phase 3 development as an on-demand hormone-free contraceptive (topline data expected by year-end) and in Phase 2b development for the prevention of STDs chlamydia and gonorrhea.</li></ul><div class=\"tiny-share-widget\" data-id=\"3386530\" data-linked=\"Evofem advancing Amphora gel for prevention of certain STDs in women; shares ahead 15%\" data-tweet=\"$EVFM - Evofem advancing Amphora gel for prevention of certain STDs in women; shares ahead 15% https://seekingalpha.com/news/3386530-evofem-advancing-amphora-gel-for-prevention-of-certain-stds-in-women-shares-ahead-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3386530-evofem-advancing-amphora-gel-for-prevention-of-certain-stds-in-women-shares-ahead-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386527\" data-ts=\"1535557034\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NXTTF\" target=\"_blank\">NXTTF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386527-namaste-announces-supply-agreement-kief-cannabis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Namaste announces supply agreement with Kief Cannabis</a></h4><ul>     <li>Namaste Technologies (<a href='https://seekingalpha.com/symbol/NXTTF' title='Namaste Technologies Inc'>OTCQB:NXTTF</a> <font color='green'>+3.4%</font>) says that the Company has signed a wholesale supply agreement with Manitoba-based, late-stage ACMPR applicant, Kief Cannabis Company Ltd.</li>     <li>Under the terms of the Supply Agreement, Namaste will purchase bulk cannabis products under the Company's wholly-owned subsidiary, Cannmart to offer in its online platform.</li><li><a href=\"https://seekingalpha.com/pr/17256272-namaste-announces-supply-agreement-kief-cannabis\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3386527\" data-linked=\"Namaste announces supply agreement with Kief Cannabis\" data-tweet=\"$NXTTF - Namaste announces supply agreement with Kief Cannabis https://seekingalpha.com/news/3386527-namaste-announces-supply-agreement-kief-cannabis?source=tweet\" data-url=\"https://seekingalpha.com/news/3386527-namaste-announces-supply-agreement-kief-cannabis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386526\" data-ts=\"1535555815\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWOU\" target=\"_blank\">TWOU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386526-da-davidson-starts-2u-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DA Davidson starts 2U at Buy</a></h4><ul><li>        DA Davidson initiates 2U (NASDAQ:<a href='https://seekingalpha.com/symbol/TWOU' title='2U, Inc.'>TWOU</a>) at Buy with a $98 price target, a 14% upside to yesterday&rsquo;s close.</li><li>               Source: StreetAccount.&nbsp;</li><li>               2U shares are&nbsp;<font color='green'>up 1%</font>&nbsp;to $86.79.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3386526\" data-linked=\"DA Davidson starts 2U at Buy\" data-tweet=\"$TWOU - DA Davidson starts 2U at Buy https://seekingalpha.com/news/3386526-da-davidson-starts-2u-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3386526-da-davidson-starts-2u-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386524\" data-ts=\"1535554880\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPNT\" target=\"_blank\">OPNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386524-healthcare-top-5-gainers-losers-of-11-00-08-29-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 AM (08/29/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a> <font color='green'>+49%</font>. <a href='https://seekingalpha.com/symbol/GKOS' title='Glaukos'>GKOS</a> <font color='green'>+34%</font>. <a href='https://seekingalpha.com/symbol/SPHS' title='Sophiris Bio'>SPHS</a> <font color='green'>+29%</font>. <a href='https://seekingalpha.com/symbol/EVFM' title='Evofem Biosciences, Inc.'>EVFM</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a> <font color='green'>+16%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ASRT' title='Assertio Therapeutics Inc'>ASRT</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/ORGS' title='Orgenesis, Inc.'>ORGS</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/IRMD' title='iRadimed Corp.'>IRMD</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3386524\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 AM (08/29/2018)\" data-tweet=\"$OPNT $OPNT $GKOS - Healthcare - Top 5 Gainers / Losers as of 11:00 AM (08/29/2018) https://seekingalpha.com/news/3386524-healthcare-top-5-gainers-losers-of-11-00-08-29-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3386524-healthcare-top-5-gainers-losers-of-11-00-08-29-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386523\" data-ts=\"1535554844\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TOUR\" target=\"_blank\">TOUR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386523-tuniu-corporation-down-9_2-post-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tuniu Corporation down 9.2% post Q2 results</a></h4><ul><li>Tuniu Corporation (<a href='https://seekingalpha.com/symbol/TOUR' title='Tuniu Corporation'>TOUR</a> <font color='red'>-9.2%</font>) <a href=\"https://seekingalpha.com/pr/17255988-tuniu-announces-unaudited-second-quarter-2018-financial-results\" target=\"_blank\">reports Q2</a> revenue growth of 14.2% Y/Y to RMB525.25M&nbsp;&nbsp;&nbsp; .</li><li>Packaged tours revenues were RMB437.6M (+29% Y/Y), the increase was primarily due to the growth of organized tours.</li><li>Other revenues were RMB87.6M (-27.4% Y/Y).</li><li>Gross profit was RMB250.8M (+4.2% Y/Y), the increase was primarily due to the increase in efficiency resulting from economies of scale.</li><li>Adj. operating expenses were RMB312M (-33.8% Y/Y).</li><li>The Company had cash, equivalents, restricted cash and short-term investments of RMB1.9B.</li><li><strong>Q3 Outlook:</strong> Net revenues of RMB725.5-765.8M, which represents 5-10% decrease Y/Y.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386361-tuniu-beats-rmb0_25-misses-revenue\" target=\"_blank\">Tuniu beats by RMB0.25, misses on revenue</a> (Aug. 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3386523\" data-linked=\"Tuniu Corporation down 9.2% post Q2 results\" data-tweet=\"$TOUR - Tuniu Corporation down 9.2% post Q2 results https://seekingalpha.com/news/3386523-tuniu-corporation-down-9_2-post-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3386523-tuniu-corporation-down-9_2-post-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386517\" data-ts=\"1535554286\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DY\" target=\"_blank\">DY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386517-dycomplus-5-post-q2-results-reaffirms-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dycom +5% post Q2 results, reaffirms guidance</a></h4><ul><li>Dycom Industries (<a href='https://seekingalpha.com/symbol/DY' title='Dycom Industries Inc.'>DY</a> <font color='green'>+5.4%</font>) reported Q2 revenue growth of 2.5% Y/Y to $799.47M and +0.8% on organic basis.</li><li>Q2 Adj. EBITDA was $97.83M (-17.1% Y/Y) and margin&nbsp;<font color='red'>declined by 290 bps</font>&nbsp;to 12.2%.</li><li>G&amp;A expenses were $65.55M up by 8.5% Y/Y.</li><li>3Q19 Guidance, reaffirmed: EPS of $0.80-1.04; GAAP EPS $0.69-0.93; Revenue of $785-835M and Adj. EBITDA margin 11.6-12.2%.</li><li>FY19 Guidance, reaffirmed: EPS of $2.62-3.07; GAAP EPS $2.17-2.62; Revenue of $3.01-3.11B and Adj. EBITDA margin 10.7-11.1%.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386356-dycom-industries-misses-0_03-revenue-line\" target=\"_blank\">Dycom Industries misses by $0.03,  revenue in-line</a> (Aug. 29)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3381936-dycom-minus-21-percent-steep-cuts-quarterly-full-year-guidance\" target=\"_blank\">Dycom -21% after steep cuts in quarterly, full-year guidance</a> (Aug. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3386517\" data-linked=\"Dycom +5% post Q2 results, reaffirms guidance\" data-tweet=\"$DY - Dycom +5% post Q2 results, reaffirms guidance https://seekingalpha.com/news/3386517-dycomplus-5-post-q2-results-reaffirms-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3386517-dycomplus-5-post-q2-results-reaffirms-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386519\" data-ts=\"1535554028\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NCR\" target=\"_blank\">NCR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386519-ncr-appoints-ge-cbs-radio-vet-cfo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NCR appoints GE, CBS Radio vet as CFO</a></h4><ul><li>        NCR (NYSE:<a href='https://seekingalpha.com/symbol/NCR' title='NCR Corporation'>NCR</a>) <a href=\"https://seekingalpha.com/pr/17256191-ncr-announces-new-chief-financial-officer\" target=\"_blank\">appoints</a> GE veteran Andre Fernandez as CFO effective immediately.</li><li>Fernandez most recently served as CEO of CBS Radio, where he helped prepare the company for a potential IPO before Entercom acquired it.&nbsp;&nbsp;</li><li>        CFO Bob Fishman had previously announced his retirement.</li><li>               NCR shares are&nbsp;<font color='red'>down 1.7%</font>&nbsp;to $28.54.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3386519\" data-linked=\"NCR appoints GE, CBS Radio vet as CFO\" data-tweet=\"$NCR - NCR appoints GE, CBS Radio vet as CFO https://seekingalpha.com/news/3386519-ncr-appoints-ge-cbs-radio-vet-cfo?source=tweet\" data-url=\"https://seekingalpha.com/news/3386519-ncr-appoints-ge-cbs-radio-vet-cfo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386510\" data-ts=\"1535553050\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386510-crude-futures-rise-post-inventory-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude futures rise further post inventory data</a></h4><ul>     <li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories:</a> Crude <strong>-2.6M</strong> barrels vs. -0.7M consensus, -5.8M last week.</li><li>Gasoline <strong>-1.6M</strong> barrels vs. +0.4M consensus, +1.2M last week.</li><li>Distillates <strong>-0.8M</strong> barrels vs. +1.6M consensus, +1.8M last week.</li><li>Futures&nbsp;<font color='green'>+0.80%</font>&nbsp;to $69.08.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='Invesco DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3386510\" data-linked=\"Crude futures rise further post inventory data\" data-tweet=\"$USO $OIL $UCO - Crude futures rise further post inventory data https://seekingalpha.com/news/3386510-crude-futures-rise-post-inventory-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3386510-crude-futures-rise-post-inventory-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>42&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386506\" data-ts=\"1535552444\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GTBIF\" target=\"_blank\">GTBIF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386506-green-thumb-industries-up-13-post-earnings-cooperman-invests\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Green Thumb Industries up 13% post-earnings; Cooperman invests</a></h4><ul><li>Green Thumb (<a href='https://seekingalpha.com/symbol/GTBIF' title='Green Thumb Industries Inc.'>OTCQX:GTBIF</a>) last night <a href=\"https://seekingalpha.com/news/3386270-green-thumb-industries-and-nbsp-beats-0_02\" target=\"_blank\">reported</a> revenue as up 25% Q/Q and 291% Y/Y, and positive adjusted EBITDA of $500K.</li><li>Business Insider, meanwhile, <a href=\"https://www.businessinsider.com/hedge-fund-billionaire-leon-cooperman-investing-in-marijuana-2018-8\" target=\"_blank\">reports that </a>hedge-funder Leon Cooperman has personally invested in Green Thumb.</li><li>Shares are&nbsp;<font color='green'>up 13.5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3386506\" data-linked=\"Green Thumb Industries up 13% post-earnings; Cooperman invests\" data-tweet=\"$GTBIF - Green Thumb Industries up 13% post-earnings; Cooperman invests https://seekingalpha.com/news/3386506-green-thumb-industries-up-13-post-earnings-cooperman-invests?source=tweet\" data-url=\"https://seekingalpha.com/news/3386506-green-thumb-industries-up-13-post-earnings-cooperman-invests\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386503\" data-ts=\"1535551778\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MOV\" target=\"_blank\">MOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386503-movadominus-12-after-outlook-disappoints\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Movado -12% after outlook disappoints</a></h4><ul> <li>Shares of Movado (NYSE:<a href='https://seekingalpha.com/symbol/MOV' title='Movado Group, Inc.'>MOV</a>) <font color='red'>peel off 12%</font> after the company sets full-year guidance below expectations.</li> <li>Movado guided for FY19 revenue of $660M to $675M vs. $638M consensus and FY19 EPS of $2.45 to $2.55 vs. $2.41 consensus (single analyst).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386382-movado-raised-fy2019-guidance\" target=\"_blank\">Movado raised FY2019 guidance</a> (Aug. 29)</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3386503\" data-linked=\"Movado -12% after outlook disappoints\" data-tweet=\"$MOV - Movado -12% after outlook disappoints https://seekingalpha.com/news/3386503-movadominus-12-after-outlook-disappoints?source=tweet\" data-url=\"https://seekingalpha.com/news/3386503-movadominus-12-after-outlook-disappoints\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386501\" data-ts=\"1535551303\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386501-faang-short-positionsplus-42-in-past-year\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FAANG short positions +42% in past year</a></h4><ul><li>        Short positions against the FAANG stocks have increased 42% in the past year to about $37B worth, according to <a href=\"https://www.bloomberg.com/news/articles/2018-08-29/short-bets-against-faang-stocks-have-surged-to-37-billion?utm_campaign=socialflow-organic&amp;cmpid=socialflow-twitter-business&amp;utm_source=twitter&amp;utm_medium=social&amp;utm_content=business\" target=\"_blank\">Bloomberg and S3 Partners</a> data.</li><li>               Amazon (<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a> <font color='green'>+1.4%</font>) has the most short interest with almost $10B. &nbsp;The other FAANG stocks are Facebook (<a href='https://seekingalpha.com/symbol/FB' title='Facebook'>FB</a> <font color='red'>-0.2%</font>), Apple (<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a> <font color='green'>+0.4%</font>), Netflix (<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a> <font color='red'>-1.2%</font>), and Alphabet (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a> <font color='green'>+1%</font>)(<a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a> <font color='green'>+1%</font>).&nbsp;</li><li>               Tech companies overall make up half of the 10 largest short positions in the world with Alibaba (<a href='https://seekingalpha.com/symbol/BABA' title='Alibaba Group Holding Limited'>BABA</a> <font color='red'>-0.5%</font>) topping at $19B due to the US-China trade tensions and the company&rsquo;s Ele.me food delivery bet.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386453-morgan-stanley-gives-alphabet-street-high-target-sees-175b-waymo\" target=\"_blank\">Morgan Stanley gives Alphabet Street-high target, sees $175B for Waymo</a> (Aug. 29)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386448-morgan-stanley-raises-amazon-target-implies-1_2t-value\" target=\"_blank\">Morgan Stanley raises Amazon target, implies $1.2T value</a> (Aug. 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3386501\" data-linked=\"FAANG short positions +42% in past year\" data-tweet=\"$AMZN $AMZN $FB - FAANG short positions +42% in past year https://seekingalpha.com/news/3386501-faang-short-positionsplus-42-in-past-year?source=tweet\" data-url=\"https://seekingalpha.com/news/3386501-faang-short-positionsplus-42-in-past-year\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>97&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386499\" data-ts=\"1535551117\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KPTI\" target=\"_blank\">KPTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386499-karyopharm-up-4-ahead-of-presentation-of-selinexor-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Karyopharm up 4% ahead of presentation of selinexor data</a></h4><ul><li>Karyopharm Therapeutics (<a href='https://seekingalpha.com/symbol/KPTI' title='Karyopharm Therapeutics Inc.'>KPTI</a> <font color='green'>+3.8%</font>) is up on below-average volume on the heels of its <a href=\"https://seekingalpha.com/pr/17255854-karyopharm-present-phase-2b-storm-data-evaluating-selinexor-patients-penta-refractory\" target=\"_blank\">announcement </a>that data from its Phase 2b STORM study evaluating selinexor in heavily pretreated patients with refractory multiple myeloma will be presented at the Society of Hematologic Oncology &#40;SOHO&#41; Annual Meeting in Houston, TX, September 12-15.</li><li>Patients receiving selinexor + dexamethasone experienced a 25.4% overall response rate &#40;ORR&#41;, including two complete responders. Median duration of response was 4.4 months and median overall survival was 8.6 months.</li><li>The ORR in patients previously treated with J&amp;J's Darzalex (daratumumab) (combo regimens) was 27.3%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3386499\" data-linked=\"Karyopharm up 4% ahead of presentation of selinexor data\" data-tweet=\"$KPTI - Karyopharm up 4% ahead of presentation of selinexor data https://seekingalpha.com/news/3386499-karyopharm-up-4-ahead-of-presentation-of-selinexor-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3386499-karyopharm-up-4-ahead-of-presentation-of-selinexor-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386498\" data-ts=\"1535551070\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386498-eaton-vance-slides-2_4-net-inflows-growth-slows-from-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eaton Vance slides 2.4% as net inflows growth slows from Q2</a></h4><ul><li>Eaton Vance&nbsp;<font color='red'>falls 2.4%</font>&nbsp;in early trading after <a href=\"https://seekingalpha.com/pr/17256355-eaton-vance-corp-report-three-nine-month-periods-ended-july-31-2018\" target=\"_blank\">Q3 consolidated net inflows</a> of $3.7B represent an annualized internal growth rate in managed assets of 3%, slower than the 4% rate in Q2 and 9% rate in Q3 2017.</li><li>Q3 adjusted EPS of 82 cents beat consensus by a penny and rose from 77 cents in Q2 and 62 cents in the year-ago period.</li><li>Annualized internal management fee revenue growth rate also slowed to 5% during the quarter from 7% in the prior quarter and 6% in the year-ago quarter.</li><li>Consolidated assets under management rose 3% to $453.2B as of July 31, 2018 from $440.1B as of April 30, 2018; year-ago AUM was $405.6B.</li><li>Market value change increased assets under management by $9.38B during the quarter vs. reducing AUM by $13.6B in Q2. In the year-ago period market value change boosted AUM by $9.44B.</li><li>\"In the third quarter of fiscal 2018, Eaton Vance reached new highs in managed assets, revenue and profits, both on a&nbsp;U.S.&nbsp;GAAP basis and as adjusted,\" says Chairman and CEO&nbsp;Thomas E. Faust Jr.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386456-eaton-vance-beats-0_01-revenue-line\" target=\"_blank\">Eaton Vance beats by $0.01,  revenue in-line</a> (Aug. 29)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3370377-eaton-vance-june-aum-slightly-compared-q2-end\" target=\"_blank\">Eaton Vance June AUM up slightly compared with Q2 end</a> (July 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3386498\" data-linked=\"Eaton Vance slides 2.4% as net inflows growth slows from Q2\" data-tweet=\"Eaton Vance slides 2.4% as net inflows growth slows from Q2 https://seekingalpha.com/news/3386498-eaton-vance-slides-2_4-net-inflows-growth-slows-from-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3386498-eaton-vance-slides-2_4-net-inflows-growth-slows-from-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386493\" data-ts=\"1535550354\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVDL\" target=\"_blank\">AVDL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386493-avadel-pharmas-noctiva-shows-positive-effect-in-late-stage-nocturia-study-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Avadel Pharma&#39;s Noctiva shows positive effect in late-stage nocturia study; shares up 1%</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17256332-new-data-noctiva-presented-2018-international-continence-society-meeting\" target=\"_blank\">Updated data</a> from a Phase 3 clinical trial evaluating Avadel Pharmaceuticals' (<a href='https://seekingalpha.com/symbol/AVDL' title='Avadel Pharmaceuticals plc'>AVDL</a> <font color='green'>+1.4%</font>) NOCTIVA (desmopressin acetate) Nasal Spray for the treatment of nocturia (waking at night to urinate) showed a treatment effect. The results were presented at the International Continence Society Meeting in Philadelphia.</li><li>The first uninterrupted sleep period &#40;FUSP&#41; improved to greater than four hours from an average baseline of 2.4 - 2.5 hours in treated patients.</li><li>Reducing the number of nocturic voids &#40;NOV&#41; and extending FUSP correlated with improvements in quality-of-life measures.</li><li>The FDA approved NOCTIVA in March 2017.</li></ul><div class=\"tiny-share-widget\" data-id=\"3386493\" data-linked=\"Avadel Pharma&#39;s Noctiva shows positive effect in late-stage nocturia study; shares up 1%\" data-tweet=\"$AVDL - Avadel Pharma&#39;s Noctiva shows positive effect in late-stage nocturia study; shares up 1% https://seekingalpha.com/news/3386493-avadel-pharmas-noctiva-shows-positive-effect-in-late-stage-nocturia-study-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3386493-avadel-pharmas-noctiva-shows-positive-effect-in-late-stage-nocturia-study-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386488\" data-ts=\"1535550129\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAR\" target=\"_blank\">CAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386488-spotlight-on-car-rental-pricing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spotlight on car rental pricing</a></h4><ul> <li>Car rental stocks could see some trading volatility once again after Goldman Sachs points to weak pricing in the sector.</li> <li>A survey by the firm showed pricing is down 4.4% Y/Y in Q3 to date, per Bloomberg.</li> <li>Goldman has Sell ratings issued on both Avis Budget (<a href='https://seekingalpha.com/symbol/CAR' title='Avis Budget Group, Inc.'>CAR</a> <font color='red'>-1%</font>) and Hertz Global (<a href='https://seekingalpha.com/symbol/HTZ' title='Hertz Global Holdings, Inc.'>HTZ</a> <font color='red'>-1.5%</font>).</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3386488\" data-linked=\"Spotlight on car rental pricing\" data-tweet=\"$CAR $CAR $HTZ - Spotlight on car rental pricing https://seekingalpha.com/news/3386488-spotlight-on-car-rental-pricing?source=tweet\" data-url=\"https://seekingalpha.com/news/3386488-spotlight-on-car-rental-pricing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386482\" data-ts=\"1535549606\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WTW\" target=\"_blank\">WTW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386482-weight-watchers-gains-after-oppenheimer-calls-out-transformation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weight Watchers gains after Oppenheimer calls out transformation</a></h4><ul> <li>Shares of Weight Watchers (<a href='https://seekingalpha.com/symbol/WTW' title='Weight Watchers International, Inc.'>WTW</a> <font color='green'>+3.2%</font>) track higher Oppenheimer initiates coverage with an Outperform rating on its view that a \"significant\" transformation is taking place.</li> <li>\"WTW is now tactfully introducing improved programming upon an enhanced digital infrastructure, so as to better connect with a larger and more diverse audience of subscribers,\" write analyst Brian Nagel and team.</li> <li>\"For investors, the new WTW strategy suggests the potential for a sustained, stronger and higher margin growth trajectory,\" reads the note.</li> <li>Oppy assigns a 12-18 month price target of $98 to WTW off its expectation for 2019 EPS of $3.86 and 2020 EPS of $4.90.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3386482\" data-linked=\"Weight Watchers gains after Oppenheimer calls out transformation\" data-tweet=\"$WTW $WW - Weight Watchers gains after Oppenheimer calls out transformation https://seekingalpha.com/news/3386482-weight-watchers-gains-after-oppenheimer-calls-out-transformation?source=tweet\" data-url=\"https://seekingalpha.com/news/3386482-weight-watchers-gains-after-oppenheimer-calls-out-transformation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386480\" data-ts=\"1535549060\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPNT\" target=\"_blank\">OPNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386480-premarket-gainers-of-9-05-08-29-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am (08/29/2018)</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a> <font color='green'>+79%</font>&nbsp;on EBS <a href=\"https://seekingalpha.com/news/3386449-opiant-pharma-73-percent-premarket-ebs-takeout-adapt-pharma\" target=\"_blank\">takeout</a> of Adapt Pharma.</li>     <li><a href='https://seekingalpha.com/symbol/GKOS' title='Glaukos'>GKOS</a> <font color='green'>+36%</font>&nbsp;on Alcon <a href=\"https://seekingalpha.com/news/3386400-glaukos-18-percent-premarket-alcon-voluntary-withdrawal-rival-eye-stent\" target=\"_blank\">voluntary withdrawal</a> of rival eye stent.</li>     <li><a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a> <font color='green'>+36%</font>&nbsp;as global medical cannabis market set to <a href=\"https://seekingalpha.com/pr/17256466-global-medical-cannabis-value-set-grow-legalization-efforts-continue\" target=\"_blank\">grow</a>.</li>     <li><a href='https://seekingalpha.com/symbol/WPRT' title='Westport Fuel Systems, Inc.'>WPRT</a> <font color='green'>+31%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17255892-westport-fuel-systems-weichai-westport-commercialize-hpdi-2_0-technology-china\" target=\"_blank\">entering</a> into&nbsp;&nbsp;entered into definitive development and supply agreements with Weichai Westport.</li>     <li><a href='https://seekingalpha.com/symbol/BLDP' title='Ballard Power Systems, Inc.'>BLDP</a> <font color='green'>+21%</font>&nbsp;on historic <a href=\"https://seekingalpha.com/news/3386396-ballard-roars-historic-collaboration\" target=\"_blank\">collaboration</a>.</li>     <li><a href='https://seekingalpha.com/symbol/SPHS' title='Sophiris Bio'>SPHS</a> <font color='green'>+21%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3386434-sophiris-bio-8-percent-premarket-resolution-patient-death-investigation-mid-stage-topsalysin\" target=\"_blank\">resolution</a> of patient death investigation in mid-stage topsalysin study.</li>     <li><a href='https://seekingalpha.com/symbol/AFMD' title='Affimed Therapeutics'>AFMD</a> <font color='green'>+18%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/IZEA' title='IZEA Worldwide, Inc.'>IZEA</a> <font color='green'>+14%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3386385-izea-expands-relationship-fortune-10-customer\" target=\"_blank\">expands relationship</a> with Fortune 10 customer.</li>     <li><a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a> <font color='green'>+14%</font>&nbsp;on Q2 <a href=\"https://seekingalpha.com/news/3386273-tilray-misses-0_08-beats-revenue\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/SCVL' title='Shoe Carnival, Inc.'>SCVL</a> <font color='green'>+14%</font>&nbsp;on Q2 <a href=\"https://seekingalpha.com/news/3386272-shoe-carnival-beats-0_21-beats-revenue\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/UIS' title='Unisys Corporation'>UIS</a> <font color='green'>+7%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3386320-unisys-plus-7_5-percent-move-smallcap-600-vac-moves-midcap-400\" target=\"_blank\">moving</a> to SmallCap 600.</li>     <li><a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group, Inc.'>CRON</a> <font color='green'>+6%</font>&nbsp;on cannabis <a href=\"https://seekingalpha.com/news/3386443-cronos-group-6-percent-premarket-cannabis-jv-colombia\" target=\"_blank\">JV</a> in Colombia.</li>     <li><a href='https://seekingalpha.com/symbol/CSIQ' title='Canadian Solar Inc.'>CSIQ</a> <font color='green'>+6%</font>&nbsp;on buyout <a href=\"https://seekingalpha.com/news/3386435-canadian-solar-nearly-4-percent-buyout-interest\" target=\"_blank\">interest</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3386480\" data-linked=\"Premarket Gainers as of 9:05 am (08/29/2018)\" data-tweet=\"$OPNT $OPNT $GKOS - Premarket Gainers as of 9:05 am (08/29/2018) https://seekingalpha.com/news/3386480-premarket-gainers-of-9-05-08-29-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3386480-premarket-gainers-of-9-05-08-29-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386478\" data-ts=\"1535549053\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RARE\" target=\"_blank\">RARE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386478-ultragenyx-up-3-premarket-on-fda-sign-off-early-filing-of-nda-for-ux007\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ultragenyx up 3% premarket on FDA sign-off early filing of NDA for UX007</a></h4><ul><li>Ultragenyx Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/RARE' title='Ultragenyx Pharmaceutical Inc.'>RARE</a>) is up&nbsp;<font color='green'>3%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/17256310-ultragenyx-announces-fda-accepts-proposal-submit-nda-ux007-treatment-long-chain-fatty-acid\" target=\"_blank\">announcement </a>that the FDA is on board with its proposal to submit a marketing application seeking approval for UX007 for the treatment of long-chain fatty acid oxidation disorders based on existing Phase 2 data. A pre-NDA meeting is on tap for later this year.</li><li>The company says it plans to discuss the data with the European Medicines Agency and will update investors at a later time this year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3386478\" data-linked=\"Ultragenyx up 3% premarket on FDA sign-off early filing of NDA for UX007\" data-tweet=\"$RARE - Ultragenyx up 3% premarket on FDA sign-off early filing of NDA for UX007 https://seekingalpha.com/news/3386478-ultragenyx-up-3-premarket-on-fda-sign-off-early-filing-of-nda-for-ux007?source=tweet\" data-url=\"https://seekingalpha.com/news/3386478-ultragenyx-up-3-premarket-on-fda-sign-off-early-filing-of-nda-for-ux007\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386475\" data-ts=\"1535548805\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HEAR\" target=\"_blank\">HEAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386475-turtle-beachplus-1_3-on-gaming-audio-system-launch\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Turtle Beach +1.3% on gaming audio system launch</a></h4><ul><li>        Turtle Beach (NASDAQ:<a href='https://seekingalpha.com/symbol/HEAR' title='Turtle Beach Corporation'>HEAR</a>) <a href=\"https://seekingalpha.com/pr/17256286-turtle-beach-unveils-elite-pro-2-superamp-pro-performance-gaming-audio-system-xbox-one\" target=\"_blank\">announces</a> the Elite Pro 2 + SuperAmp Pro Performance gaming audio system for the Xbox One and PlayStation 4.</li><li>               The system will launch on September 16 in North America and October 8 in the UK and Europe with an MSRP of $249.95.</li><li>               Turtle Beach shares are<font color='green'> up 1.3%</font>&nbsp;premarket to $24.54. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3386475\" data-linked=\"Turtle Beach +1.3% on gaming audio system launch\" data-tweet=\"$HEAR - Turtle Beach +1.3% on gaming audio system launch https://seekingalpha.com/news/3386475-turtle-beachplus-1_3-on-gaming-audio-system-launch?source=tweet\" data-url=\"https://seekingalpha.com/news/3386475-turtle-beachplus-1_3-on-gaming-audio-system-launch\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386472\" data-ts=\"1535548566\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RACE\" target=\"_blank\">RACE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386472-hsbc-sees-ferrari-racing-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HSBC sees Ferrari racing higher</a></h4><ul> <li>HSBC Securities upgrades Ferrari (NYSE:<a href='https://seekingalpha.com/symbol/RACE' title='Ferrari N.V.'>RACE</a>) to a Buy rating from Hold.</li> <li>HSBC sees an opportunity for investors after Ferrari was bid down following cautious guidance. Cash generation is expected to significantly improve when investments made in 2018-19 start to bear fruit.</li>  <li>Shares of Ferrari are <font color='green'>up 2.05%</font> in premarket trading to $132.70. The 52-week high is $149.85.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3386472\" data-linked=\"HSBC sees Ferrari racing higher\" data-tweet=\"$RACE - HSBC sees Ferrari racing higher https://seekingalpha.com/news/3386472-hsbc-sees-ferrari-racing-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3386472-hsbc-sees-ferrari-racing-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386469\" data-ts=\"1535548255\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASRT\" target=\"_blank\">ASRT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386469-premarket-losers-of-9-05-8-29-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am (8/29/2018)</a></h4><ul><li><a href='https://seekingalpha.com/symbol/ASRT' title='Assertio Therapeutics Inc'>ASRT</a>&nbsp;<font color='red'>-15%</font>&nbsp;after <a href=\"https://seekingalpha.com/news/3386301-assertio-settles-oxycontin-patent-dispute-purdue-pharma-62m-shares-4-percent-hours\" target=\"_blank\">settling</a> its patent infringement litigation with Purdue Pharma L.P.</li><li><a href='https://seekingalpha.com/symbol/YRD' title='Yirendai LTD.'>YRD</a>&nbsp;<font color='red'>-8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3386319-yirendai-beats-0_44-misses-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/DKS' title='Dick&#39;s Sporting Goods, Inc.'>DKS</a>&nbsp;<font color='red'>-8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3386399-dicks-sporting-goods-beats-0_14-misses-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/BOX' title='Box'>BOX</a>&nbsp;<font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3386271-box-beats-0_01-beats-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/AEO' title='American Eagle Outfitters, Inc.'>AEO</a>&nbsp;<font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3386416-american-eagle-outfitters-beats-0_03-beats-revenue\" target=\"_blank\">Q2 earnings</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3386469\" data-linked=\"Premarket Losers as of 9:05 am (8/29/2018)\" data-tweet=\"$ASRT $ASRT $YRD - Premarket Losers as of 9:05 am (8/29/2018) https://seekingalpha.com/news/3386469-premarket-losers-of-9-05-8-29-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3386469-premarket-losers-of-9-05-8-29-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386468\" data-ts=\"1535547972\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZUO\" target=\"_blank\">ZUO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386468-needham-raises-zuora-to-street-high-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Needham raises Zuora to Street-high target</a></h4><ul><li>        Needham <a href=\"https://www.streetinsider.com/Analyst+PT+Change/Zuora+Inc.+%28ZUO%29+PT+Raised+to+Street+High+%2438+at+Needham+%26+Company/14557624.html\" target=\"_blank\">raises</a> its Zuora (NYSE:<a href='https://seekingalpha.com/symbol/ZUO' title='Zuora, Inc.'>ZUO</a>) target from $33 to $38, a 17.5% upside to yesterday&rsquo;s close and a new Street-high target.</li><li>               Rating maintained at Buy.&nbsp;</li><li>               Zuora shares are&nbsp;<font color='green'>up 1.3%</font>&nbsp;premarket to $32.75.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3386468\" data-linked=\"Needham raises Zuora to Street-high target\" data-tweet=\"$ZUO - Needham raises Zuora to Street-high target https://seekingalpha.com/news/3386468-needham-raises-zuora-to-street-high-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3386468-needham-raises-zuora-to-street-high-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386460\" data-ts=\"1535547651\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UPLD\" target=\"_blank\">UPLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386460-esw-lowers-active-stake-in-upland-software\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ESW lowers active stake in Upland Software</a></h4><ul><li>        ESW Capital lowers its active stake in Upland Software (NASDAQ:<a href='https://seekingalpha.com/symbol/UPLD' title='Upland Software'>UPLD</a>) <a href=\"https://seekingalpha.com/filing/3794910\" target=\"_blank\">from 13.5%</a> to <a href=\"https://seekingalpha.com/filing/4152863\" target=\"_blank\">8.4%.</a> </li><li>        Upland shares are&nbsp;<font color='red'>down 1.6%</font>&nbsp;premarket to $36.33.&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3386460\" data-linked=\"ESW lowers active stake in Upland Software\" data-tweet=\"$UPLD - ESW lowers active stake in Upland Software https://seekingalpha.com/news/3386460-esw-lowers-active-stake-in-upland-software?source=tweet\" data-url=\"https://seekingalpha.com/news/3386460-esw-lowers-active-stake-in-upland-software\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386461\" data-ts=\"1535547651\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WTW\" target=\"_blank\">WTW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386461-weight-watchers-up-1_2-oppenheimer-launches-coverage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weight Watchers up 1.2% as Oppenheimer launches coverage</a></h4><ul><li>\"A significant transformation is taking place at Weight Watchers (NYSE:<a href='https://seekingalpha.com/symbol/WTW' title='Weight Watchers International, Inc.'>WTW</a>),\" says analyst Brain Nagel, starting coverage with an Outperform rating. His $98 price target suggests&nbsp;<font color='green'>nearly 30% upside</font>.</li><li>He takes note of new CEO Mindy Grossman's digital strategy. The recent decline in the stock price, says Nagel, is at odds with strengthening fundamentals.</li><li>Source: Bloomberg</li><li>Shares&nbsp;<font color='green'>up 1.2%&nbsp;</font>premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3386461\" data-linked=\"Weight Watchers up 1.2% as Oppenheimer launches coverage\" data-tweet=\"$WTW $WW - Weight Watchers up 1.2% as Oppenheimer launches coverage https://seekingalpha.com/news/3386461-weight-watchers-up-1_2-oppenheimer-launches-coverage?source=tweet\" data-url=\"https://seekingalpha.com/news/3386461-weight-watchers-up-1_2-oppenheimer-launches-coverage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386458\" data-ts=\"1535547636\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVGR\" target=\"_blank\">AVGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386458-avinger-receives-new-patent-covering-pantheris-image-guided-atherectomy-system\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Avinger receives new patent covering pantheris image-guided atherectomy system</a></h4><ul><li>Avinger (NASDAQ:<a href='https://seekingalpha.com/symbol/AVGR' title='Avinger'>AVGR</a>) <a href=\"https://seekingalpha.com/pr/17256306-avinger-receives-new-patent-covering-pantheris-image-guided-atherectomy-system\" target=\"_blank\">announces</a> the issuance of an important new patent covering the Company&rsquo;s Pantheris image-guided atherectomy system.</li>   <li>The USPTO issued U.S. Patent No. 10,052,125, titled &ldquo;Atherectomy Catheter With Laterally-Displaceable Tip,&rdquo; on August 21.</li><li>The patent describes an atherectomy catheter (which is a device used to remove plaque from blood vessels) including real-time image guidance using optical coherence tomography, a displaceable tip and a balloon to urge the catheter&rsquo;s cutting element into the tissue to be removed.</li><li>Shares are up&nbsp;<font color='green'>4%</font>&nbsp;premarket.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3386458\" data-linked=\"Avinger receives new patent covering pantheris image-guided atherectomy system\" data-tweet=\"$AVGR - Avinger receives new patent covering pantheris image-guided atherectomy system https://seekingalpha.com/news/3386458-avinger-receives-new-patent-covering-pantheris-image-guided-atherectomy-system?source=tweet\" data-url=\"https://seekingalpha.com/news/3386458-avinger-receives-new-patent-covering-pantheris-image-guided-atherectomy-system\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386452\" data-ts=\"1535546891\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DOVA\" target=\"_blank\">DOVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386452-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Dova Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DOVA' title='Dova Pharmaceuticals'>DOVA</a>) initiated with Outperform rating and $44 (79% upside) price target at Raymond James. Shares up&nbsp;<font color='green'>6%</font>&nbsp;premarket.</li><li>Deciphera Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DCPH' title='Deciphera Pharmaceuticals, Inc.'>DCPH</a>) initiated with Outperform rating and $47 (33% upside) price target at Raymond James.</li><li>Assertio Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ASRT' title='Assertio Therapeutics Inc'>ASRT</a>) downgraded to Neutral at Janney. Shares down&nbsp;<font color='red'>15%</font>&nbsp;premarket after settling Oxycontin patent dispute with Purdue Pharma.</li></ul><div class=\"tiny-share-widget\" data-id=\"3386452\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$DOVA $DOVA $DCPH - Premarket analyst action - healthcare https://seekingalpha.com/news/3386452-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3386452-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386449\" data-ts=\"1535546673\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPNT\" target=\"_blank\">OPNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386449-opiant-pharma-up-73-premarket-on-ebs-takeout-of-adapt-pharma\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Opiant Pharma up 73% premarket on EBS takeout of Adapt Pharma</a></h4><ul><li>Thinly traded nano cap Opiant Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a>) is up&nbsp;<font color='green'>73%</font>&nbsp;premarket on increased volume on the heels of Emergent BioSolutions' announced acquisition of Adapt Pharma for up to $735M.</li><li>Adapt Pharma markets Opiant's NARCAN Nasal Spray for the emergency treatment of opioid overdose. Opiant receives 90% of the royalties and milestone payments for the product.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386298-emergent-bio-acquire-adapt-pharma-735m\" target=\"_blank\">Emergent Bio to acquire Adapt Pharma for up to $735M</a> (Aug. 28)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3329423-opiant-book-11_7m-narcan-related-income-2017-shares-11-percent-premarket\" target=\"_blank\">Opiant to book $11.7M in Narcan-related income in 2017; shares up 11% premarket</a> (Feb. 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3386449\" data-linked=\"Opiant Pharma up 73% premarket on EBS takeout of Adapt Pharma\" data-tweet=\"$OPNT - Opiant Pharma up 73% premarket on EBS takeout of Adapt Pharma https://seekingalpha.com/news/3386449-opiant-pharma-up-73-premarket-on-ebs-takeout-of-adapt-pharma?source=tweet\" data-url=\"https://seekingalpha.com/news/3386449-opiant-pharma-up-73-premarket-on-ebs-takeout-of-adapt-pharma\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386448\" data-ts=\"1535546506\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386448-morgan-stanley-raises-amazon-target-implies-1_2t-value\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley raises Amazon target, implies $1.2T value</a></h4><ul><li>        Morgan Stanley <a href=\"https://www.bloomberg.com/news/articles/2018-08-29/amazon-and-alphabet-have-a-new-number-one-fan-on-wall-street\" target=\"_blank\">becomes the biggest</a> Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) bull with a new Street-high target.</li><li>               Amazon&rsquo;s target gets a 35% boost to $2,500 from $1,850, which implies a market value of $1.2T. &nbsp;&nbsp;</li><li>               Analyst Brian Nowak cites Amazon&rsquo;s high growth, high-margin revenues from the likes of AWS, ads, and subscriptions that give the company room to invest and generate higher profits. .</li><li>                  Amazon shares are&nbsp;<font color='green'>up 1.2%</font>&nbsp;premarket to $1,956.51.&nbsp;&nbsp;&nbsp;&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3386253-bloomberg-amazon-talking-sony-paramount-streaming-rights\" target=\"_blank\">Bloomberg: Amazon talking to Sony, Paramount for streaming rights</a> (Aug. 28)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386307-roku-dips-report-amazon-plans-ad-supported-fire-tv-streaming\" target=\"_blank\">Roku dips on report of Amazon plans for ad-supported Fire TV streaming</a> (Aug. 28)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386437-amazon-expands-whole-foods-prime-now-delivery\" target=\"_blank\">Amazon expands Whole Foods Prime Now delivery</a> (Aug. 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3386448\" data-linked=\"Morgan Stanley raises Amazon target, implies $1.2T value\" data-tweet=\"$AMZN - Morgan Stanley raises Amazon target, implies $1.2T value https://seekingalpha.com/news/3386448-morgan-stanley-raises-amazon-target-implies-1_2t-value?source=tweet\" data-url=\"https://seekingalpha.com/news/3386448-morgan-stanley-raises-amazon-target-implies-1_2t-value\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386443\" data-ts=\"1535546142\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRON\" target=\"_blank\">CRON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386443-cronos-group-up-6-premarket-on-cannabis-jv-in-colombia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cronos Group up 6% premarket on cannabis JV in Colombia</a></h4><ul><li>Cronos Group (NASDAQ:<a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group, Inc.'>CRON</a>) is up&nbsp;<font color='green'>6%&nbsp;</font>premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/17256133-cronos-group-inc-unveils-platform-latam\" target=\"_blank\">announced </a>50/50 joint venture with an affiliate of Colombian agriculture services provider Agroidea SAS under an entity called NatuEra S.&agrave; r.l. The partnership will focus on the development, cultivation, manufacture and export of cannabis-based medicinal and consumer products for Latin American and global markets.</li><li>NatuEra's operations will start on 207 acres of land in Cundinamarca, Colombia.</li><li>Each partner will contribute capital to fund construction and operating costs. Former Americaflor&nbsp;CEO Nicolas Nannetti will lead the new organization.</li></ul><div class=\"tiny-share-widget\" data-id=\"3386443\" data-linked=\"Cronos Group up 6% premarket on cannabis JV in Colombia\" data-tweet=\"$CRON - Cronos Group up 6% premarket on cannabis JV in Colombia https://seekingalpha.com/news/3386443-cronos-group-up-6-premarket-on-cannabis-jv-in-colombia?source=tweet\" data-url=\"https://seekingalpha.com/news/3386443-cronos-group-up-6-premarket-on-cannabis-jv-in-colombia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386437\" data-ts=\"1535545649\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386437-amazon-expands-whole-foods-prime-now-delivery\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amazon expands Whole Foods Prime Now delivery</a></h4><ul><li>        Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) <a href=\"https://seekingalpha.com/pr/17255894-amazon-expands-grocery-delivery-whole-foods-market-columbus-dayton-portland-greater\" target=\"_blank\">expands</a> its Whole Foods Prime Now delivery to Columbus, Dayton, Portland, Greater Washington D.C., and additional areas of NYC including Greenwich Village, Chelsea, Union Square, and Murray Hill.</li><li>               The expansion pushes Whole Foods Prime Now delivery to 28 cities with plans to continue expanding across the U.S. throughout this year.&nbsp;</li><li>               Amazon shares are&nbsp;<font color='green'>up 1.2%</font>&nbsp;premarket to $1,956.55.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386253-bloomberg-amazon-talking-sony-paramount-streaming-rights\" target=\"_blank\">Bloomberg: Amazon talking to Sony, Paramount for streaming rights</a> (Aug. 28)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386307-roku-dips-report-amazon-plans-ad-supported-fire-tv-streaming\" target=\"_blank\">Roku dips on report of Amazon plans for ad-supported Fire TV streaming</a> (Aug. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3386437\" data-linked=\"Amazon expands Whole Foods Prime Now delivery\" data-tweet=\"$AMZN - Amazon expands Whole Foods Prime Now delivery https://seekingalpha.com/news/3386437-amazon-expands-whole-foods-prime-now-delivery?source=tweet\" data-url=\"https://seekingalpha.com/news/3386437-amazon-expands-whole-foods-prime-now-delivery\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386435\" data-ts=\"1535545466\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSIQ\" target=\"_blank\">CSIQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386435-canadian-solar-up-nearly-4-on-buyout-interest\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canadian Solar up nearly 4% on buyout interest</a></h4><ul><li>Holder of a sizable stake in Canadian Solar (NASDAQ:<a href='https://seekingalpha.com/symbol/CSIQ' title='Canadian Solar Inc.'>CSIQ</a>), Lion Point Capital says it's <a href=\"https://seekingalpha.com/filing/4152818\" target=\"_blank\">had talks with a number </a>of players interested in funding a privatization deal (the chairman/CEO has a bid in at $18.47).</li><li>Shares are<font color='green'> up 3.8%</font>&nbsp;premarket to $14.24.</li></ul><div class=\"tiny-share-widget\" data-id=\"3386435\" data-linked=\"Canadian Solar up nearly 4% on buyout interest\" data-tweet=\"$CSIQ - Canadian Solar up nearly 4% on buyout interest https://seekingalpha.com/news/3386435-canadian-solar-up-nearly-4-on-buyout-interest?source=tweet\" data-url=\"https://seekingalpha.com/news/3386435-canadian-solar-up-nearly-4-on-buyout-interest\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386434\" data-ts=\"1535545464\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPHS\" target=\"_blank\">SPHS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386434-sophiris-bio-up-8-premarket-on-resolution-of-patient-death-investigation-in-mid-stage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sophiris Bio up 8% premarket on resolution of patient death investigation in mid-stage topsalysin study</a></h4><ul><li>Sophiris Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/SPHS' title='Sophiris Bio'>SPHS</a>) is up&nbsp;<font color='green'>8%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/17256204-sophiris-bio-updates-phase-2b-localized-prostate-cancer-trial\" target=\"_blank\">announcement </a>of the conclusion of the investigation into a death that occurred in its Phase 2b clinical trial evaluating topsalysin in patients with localized prostate cancer.</li><li>The cause of death was determined to be Sudden Cardiac Death most likely due to an arrhythmia, not related to treatment.</li><li>Complete results will be released by year-end. A Phase 3 trial is next up.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3272372-sophiris-bios-mid-stage-study-topsalysin-prostate-cancer-underway-shares-ahead-11-percent\" target=\"_blank\">Sophiris Bio's mid-stage study of topsalysin in prostate cancer underway; shares ahead 11% premarket</a> (June 8, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3386434\" data-linked=\"Sophiris Bio up 8% premarket on resolution of patient death investigation in mid-stage topsalysin study\" data-tweet=\"$SPHS - Sophiris Bio up 8% premarket on resolution of patient death investigation in mid-stage topsalysin study https://seekingalpha.com/news/3386434-sophiris-bio-up-8-premarket-on-resolution-of-patient-death-investigation-in-mid-stage?source=tweet\" data-url=\"https://seekingalpha.com/news/3386434-sophiris-bio-up-8-premarket-on-resolution-of-patient-death-investigation-in-mid-stage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386433\" data-ts=\"1535545252\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AEO\" target=\"_blank\">AEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386433-american-eagle-outfittersminus-8-despite-strong-q2-comp\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Eagle Outfitters -8% despite strong Q2 comp</a></h4><ul> <li>American Eagle Outfitters (NYSE:<a href='https://seekingalpha.com/symbol/AEO' title='American Eagle Outfitters, Inc.'>AEO</a>) reports comparable sales increased 9% in <a href=\"https://seekingalpha.com/news/3386416-american-eagle-outfitters-beats-0_03-beats-revenue\" target=\"_blank\">Q2</a> to smash the consensus estimate for a 6.4% rise.</li> <li>The Aerie brand generated a 27% comp, while the American Eagle brand saw a 7% increase in comparable sales.</li> <li>The company's gross margin came in at 36.6% of sales vs. 35.6% consensus and 34.9% a year ago.</li> <li>Investors have bid AEO <font color='red'>down 7%</font> in premarket trading after Q3 EPS guidance arrived at $0.45 to $0.47 vs. $0.49 consensus.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386416-american-eagle-outfitters-beats-0_03-beats-revenue\" target=\"_blank\">American Eagle Outfitters beats by $0.03, beats on revenue</a> (Aug. 29)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3386433\" data-linked=\"American Eagle Outfitters -8% despite strong Q2 comp\" data-tweet=\"$AEO - American Eagle Outfitters -8% despite strong Q2 comp https://seekingalpha.com/news/3386433-american-eagle-outfittersminus-8-despite-strong-q2-comp?source=tweet\" data-url=\"https://seekingalpha.com/news/3386433-american-eagle-outfittersminus-8-despite-strong-q2-comp\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386426\" data-ts=\"1535544533\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHS\" target=\"_blank\">CHS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386426-chicos-fasplus-3-on-earnings-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chico&#39;s FAS +3% on earnings beat</a></h4><ul><li>Chico's FAS (NYSE:<a href='https://seekingalpha.com/symbol/CHS' title='Chico&#39;s FAS, Inc.'>CHS</a>) reports&nbsp;comparable sales declined 3.2% in <a href=\"https://seekingalpha.com/pr/17256106-chicos-fas-inc-reports-second-quarter-results\" target=\"_blank\">Q2</a>.</li><li>Comparable Sales beak-up: Chico's: -3.8%; White House Black Market: -3.5%; Soma: -0.9%.</li><li>Chico's sales dropped 5.1% to $286.81M, White House Black Market sales down 8.4% to 168.94M and Soma sales -3.3% to $88.97M.</li><li>Gross margin rate flat at 36.1%.</li><li>SG&amp;A expense rate increased 190 bps to 31.9%, primarily reflects investments in marketing and technology as well as deleverage of store operating expenses.</li><li>Inventories fell 4.6% to $224.2M.</li><li>The company repurchased 3.5M shares for $30.8M, at a weighted average of $8.70 per share during the quarter.</li><li>Total store count 1,440.</li><li><strong>Q3 Guidance</strong>: Net sales:&nbsp;to decline low-single digits; Comparable sales:&nbsp;to decline low-single digits; Gross margin rate: +50 bps Y/Y; SG&amp;A expenses: +$8M to +$10M.</li><li><strong>FY2018 Guidance</strong>: Net sales: mid-single digit decline; Comparable sales: low-to-mid single digit decline; Gross margin rate: +50 bps Y/Y; SG&amp;A expenses: ~flat; Tax rate: 26% to 28%; Capex: $60M to $70M.</li><li>CHS&nbsp;<font color='green'>+2.94%</font>&nbsp;premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386397-chicos-fas-beats-0_01-beats-revenue\" target=\"_blank\">Chico's FAS beats by $0.01, beats on revenue</a> (Aug. 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3386426\" data-linked=\"Chico&#39;s FAS +3% on earnings beat\" data-tweet=\"$CHS - Chico&#39;s FAS +3% on earnings beat https://seekingalpha.com/news/3386426-chicos-fasplus-3-on-earnings-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3386426-chicos-fasplus-3-on-earnings-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386420\" data-ts=\"1535544261\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BITA\" target=\"_blank\">BITA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386420-jpmorgan-assumes-chinese-internet-stocks-move\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan assumes, Chinese internet stocks move</a></h4><ul><li>        JPMorgan assumes a slate of Chinese internet stocks: Bitauto Holdings (NYSE:<a href='https://seekingalpha.com/symbol/BITA' title='Bitauto Holdings Limited'>BITA</a>) at Overweight with a $38 target, Phoenix New Media (NYSE:<a href='https://seekingalpha.com/symbol/FENG' title='Phoenix New Media Limited'>FENG</a>) at Overweight and $10; Sina (NASDAQ:<a href='https://seekingalpha.com/symbol/SINA' title='Sina Corporation'>SINA</a>) at Overweight and $150, Weibo (NASDAQ:<a href='https://seekingalpha.com/symbol/WB' title='Weibo Corporation'>WB</a>) at Overweight and $118, Autohome (NYSE:<a href='https://seekingalpha.com/symbol/ATHM' title='Autohome Inc.'>ATHM</a>) at Neutral and $80, and Fang Holdings (NYSE:<a href='https://seekingalpha.com/symbol/SFUN' title='Fang Holdings Ltd. ADS'>SFUN</a>) at Neutral and $3.60.</li><li>               Firm upgrades Leju Holdings (NYSE:<a href='https://seekingalpha.com/symbol/LEJU' title='Leju Holdings Limited'>LEJU</a>) from Neutral to Underweight and increases the target rom $1.60 to $3.60.&nbsp;</li><li>                  Premarket price movements: BITA&nbsp;<font color='red'>-1.3%</font>&nbsp;to $22.25,&nbsp; FENG&nbsp;<font color='green'>+2.4%</font>&nbsp;to $4.78, SINA&nbsp;<font color='green'>+0.3%</font>&nbsp;to $72.30, WB&nbsp;<font color='green'>+0.3%</font>&nbsp;to $80.30, SFUN&nbsp;<font color='red'>-0.3%</font>&nbsp;to $3, and LEJU&nbsp;<font color='green'>+3.1%</font>&nbsp;to $2.01.&nbsp;    </li><li>               Source: StreetAccount.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3386420\" data-linked=\"JPMorgan assumes, Chinese internet stocks move\" data-tweet=\"$BITA $BITA $FENG - JPMorgan assumes, Chinese internet stocks move https://seekingalpha.com/news/3386420-jpmorgan-assumes-chinese-internet-stocks-move?source=tweet\" data-url=\"https://seekingalpha.com/news/3386420-jpmorgan-assumes-chinese-internet-stocks-move\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386412\" data-ts=\"1535544027\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UA\" target=\"_blank\">UA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386412-under-armourminus-3-after-dicks-reports-sales-drop-for-brand\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Under Armour -3% after Dick&#39;s reports sales drop for brand</a></h4><ul> <li>Under Armour (<a href='https://seekingalpha.com/symbol/UA' title='Under Armour, Inc. Class C'>UA</a>, <a href='https://seekingalpha.com/symbol/UAA' title='Under Armour, Inc.'>UAA</a>) trades lower after Dick's management points to some weakness with the brand.</li><li>Dick's on UA:&nbsp;\"We experienced continued significant declines in Under Armour sales as a result of their decision to expand distribution.\"</li> <li>UAA <font color='red'>-2.77%</font> to $20.34. UA <font color='red'>-3.33%</font> to $18.60.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3386412\" data-linked=\"Under Armour -3% after Dick&#39;s reports sales drop for brand\" data-tweet=\"$UA $UA $UAA - Under Armour -3% after Dick&#39;s reports sales drop for brand https://seekingalpha.com/news/3386412-under-armourminus-3-after-dicks-reports-sales-drop-for-brand?source=tweet\" data-url=\"https://seekingalpha.com/news/3386412-under-armourminus-3-after-dicks-reports-sales-drop-for-brand\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386411\" data-ts=\"1535543855\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SQ\" target=\"_blank\">SQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386411-square-rises-1_6-after-named-new-best-idea-guggenheim\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Square rises 1.6% after named `new best idea&#39; at Guggenheim</a></h4><ul><li>Square (NYSE:<a href='https://seekingalpha.com/symbol/SQ' title='Square, Inc.'>SQ</a>)<font color='green'>&nbsp;gains 1.6%</font>&nbsp;in premarket trading after Guggenheim analyst Jeff Cantwell names the stock a&nbsp; \"new best idea\" and raises his price target to $100 from $75, noting that the company's revenue potential for Cash App is underappreciated, according to Bloomberg.</li><li>Cantwell sees Cash App taking an important \"services\" role for underbanked populations and sees 2019 subscription-and-services revenue of $1.02B compared with consensus of $868M. Cash App likely to spread into consumer finance, investing, and cross-border money transfer driving sustained revenue growth, he writes.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3377001-square-slips-market-action-post-q2-report\" target=\"_blank\">Square slips in after-market action post Q2 report</a> (Aug. 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3386411\" data-linked=\"Square rises 1.6% after named `new best idea&#39; at Guggenheim\" data-tweet=\"$SQ - Square rises 1.6% after named `new best idea&#39; at Guggenheim https://seekingalpha.com/news/3386411-square-rises-1_6-after-named-new-best-idea-guggenheim?source=tweet\" data-url=\"https://seekingalpha.com/news/3386411-square-rises-1_6-after-named-new-best-idea-guggenheim\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>71&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386410\" data-ts=\"1535543735\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DKS\" target=\"_blank\">DKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386410-comparable-sales-disappoint-dicks-sporting-goods\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Comparable sales disappoint at Dick&#39;s Sporting Goods</a></h4><ul> <li>Dick's Sporting Goods (NYSE:<a href='https://seekingalpha.com/symbol/DKS' title='Dick&#39;s Sporting Goods, Inc.'>DKS</a>) is <font color='red'>down 8%</font> after comparable sales fell 1.9% in <a href=\"https://seekingalpha.com/pr/17256103-dicks-sporting-goods-reports-second-quarter-results\" target=\"_blank\">Q2</a> to miss the consensus estimate for a 0.7% drop. Adjusted for calendar effects, comparable store sales were down 4.0% during the quarter.</li> <li>E-commerce sales rose 12% to account for 11% of total sales vs. 9% penetration a year ago.</li> <li>The company's gross margin rate improved 80 bps to 30.3% of sales. Operating margin was up 10 bps to 7.5% of sales.</li> <li>Dick's opened five new stores during the quarter.</li> <li>Total inventory at the end of the quarter was down 6.4% Y/Y.</li> <li>CEO update: \"We delivered double digit growth in eCommerce, private brands, and athletic apparel excluding Under Armour, however, as expected, sales were impacted by the strategic decisions we made regarding the slow growth, low margin hunt and electronics businesses, which accounted for nearly half of our comp decline. In addition, we experienced continued significant declines in Under Armour sales as a result of their decision to expand distribution. We are very confident our sales trajectory will improve next year as these headwinds are expected to subside.\"</li> <li>Looking ahead, Dick's expects full-year EPS of $3.02 to $3.20 vs. $2.92 to $3.12 prior and $3.08 consensus. Comparable store sales are anticipated to fall 3% to 4%.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386399-dicks-sporting-goods-beats-0_14-misses-revenue\" target=\"_blank\">Dick's Sporting Goods beats by $0.14, misses on revenue</a> (Aug. 29)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3386410\" data-linked=\"Comparable sales disappoint at Dick&#39;s Sporting Goods\" data-tweet=\"$DKS - Comparable sales disappoint at Dick&#39;s Sporting Goods https://seekingalpha.com/news/3386410-comparable-sales-disappoint-dicks-sporting-goods?source=tweet\" data-url=\"https://seekingalpha.com/news/3386410-comparable-sales-disappoint-dicks-sporting-goods\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386408\" data-ts=\"1535543303\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KMDA\" target=\"_blank\">KMDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386408-kamada-down-3-premarket-on-softer-revenue-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kamada down 3% premarket on softer revenue guidance</a></h4><ul><li>Kamada Ltd. (NASDAQ:<a href='https://seekingalpha.com/symbol/KMDA' title='Kamada Ltd'>KMDA</a>) slips&nbsp;<font color='red'>3%</font>&nbsp;premarket on average volume in response to its <a href=\"https://seekingalpha.com/pr/17256046-kamada-provides-updated-full-year-2018-revenue-guidance\" target=\"_blank\">lower guidance</a> for 2018 revenue, now $102M - 108M (from $116M - 120M). The company says the reason for the change is the likelihood of delayed product shipments from its Beit Kama production facility in Israel following the settlement of a labor strike. Shipments originally scheduled for this year will be supplied in Q1 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3386408\" data-linked=\"Kamada down 3% premarket on softer revenue guidance\" data-tweet=\"$KMDA - Kamada down 3% premarket on softer revenue guidance https://seekingalpha.com/news/3386408-kamada-down-3-premarket-on-softer-revenue-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3386408-kamada-down-3-premarket-on-softer-revenue-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386400\" data-ts=\"1535542405\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GKOS\" target=\"_blank\">GKOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386400-glaukos-up-18-premarket-on-alcon-voluntary-withdrawal-of-rival-eye-stent\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Glaukos up 18% premarket on Alcon voluntary withdrawal of rival eye stent</a></h4><ul><li>Glaukos (NYSE:<a href='https://seekingalpha.com/symbol/GKOS' title='Glaukos'>GKOS</a>) is up&nbsp;<font color='green'>18%</font>&nbsp;premarket on light volume in response to Novartis (NYSE:<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a>) unit Alcon's <a href=\"https://www.alcon.com/news/media-releases/alcon-announces-voluntary-global-market-withdrawal-cypass-micro-stent-surgical\" target=\"_blank\">decision </a>to voluntarily withdraw its CyPass Micro-Stent from the market due to lack of efficacy. Specifically, an analysis of five-year post-cataract surgery data from the COMPASS-XT study showed little difference in endothelial cell loss in patients receiving CyPass compared to those who underwent cataract surgery only.</li><li>The device, approved by the FDA a little over two years ago, is used to reduce intraocular pressure in glaucoma patients.</li><li>Glaukos markets its <a href=\"https://www.glaukos.com/istent-inject-procedure/\" target=\"_blank\">iStent </a>for the same indication.</li><li>Novartis is down&nbsp;<font color='red'>1%&nbsp;</font>premarket albeit on only 400 shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3386400\" data-linked=\"Glaukos up 18% premarket on Alcon voluntary withdrawal of rival eye stent\" data-tweet=\"$GKOS $GKOS $NVS - Glaukos up 18% premarket on Alcon voluntary withdrawal of rival eye stent https://seekingalpha.com/news/3386400-glaukos-up-18-premarket-on-alcon-voluntary-withdrawal-of-rival-eye-stent?source=tweet\" data-url=\"https://seekingalpha.com/news/3386400-glaukos-up-18-premarket-on-alcon-voluntary-withdrawal-of-rival-eye-stent\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386395\" data-ts=\"1535542173\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MFGP\" target=\"_blank\">MFGP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386395-micro-focusplus-1_5-on-share-buyback-program\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micro Focus +1.5% on share buyback program</a></h4><ul><li>        Micro Focus (NYSE:<a href='https://seekingalpha.com/symbol/MFGP' title='Micro Focus International plc ADR'>MFGP</a>) <a href=\"https://seekingalpha.com/filing/4152798\" target=\"_blank\">commences</a> a share buyback program with an initial tranche of up to $200M.</li><li>               Micro Focus shares are&nbsp;<font color='green'>up 1.5%</font>&nbsp;premarket to $16.98. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3386395\" data-linked=\"Micro Focus +1.5% on share buyback program\" data-tweet=\"$MFGP - Micro Focus +1.5% on share buyback program https://seekingalpha.com/news/3386395-micro-focusplus-1_5-on-share-buyback-program?source=tweet\" data-url=\"https://seekingalpha.com/news/3386395-micro-focusplus-1_5-on-share-buyback-program\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386386\" data-ts=\"1535541101\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVS\" target=\"_blank\">NVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386386-novartis-tafinlar-mekinist-okd-in-europe-for-certain-type-of-melanoma\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Novartis&#39; Tafinlar + Mekinist OK&#39;d in Europe for certain type of melanoma</a></h4><ul><li>The European Commission <a href=\"https://www.novartis.com/news/media-releases/european-commission-approves-novartis-combination-therapy-tafinlar-mekinist-adjuvant-treatment-braf-v600-mutation-positive-melanoma\" target=\"_blank\">approves </a>Novartis' (NYSE:<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a>) Tafinlar (dabrafenib) plus Mekinist (trametinib) for the adjuvant treatment of stage 3 patients with BRAF V600 mutation-positive melanoma after complete surgical resection, the third approved indication for the combo in the EU.</li><li>Shares are down&nbsp;<font color='red'>1%</font>&nbsp;premarket albeit on only 400 shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3386386\" data-linked=\"Novartis&#39; Tafinlar + Mekinist OK&#39;d in Europe for certain type of melanoma\" data-tweet=\"$NVS - Novartis&#39; Tafinlar + Mekinist OK&#39;d in Europe for certain type of melanoma https://seekingalpha.com/news/3386386-novartis-tafinlar-mekinist-okd-in-europe-for-certain-type-of-melanoma?source=tweet\" data-url=\"https://seekingalpha.com/news/3386386-novartis-tafinlar-mekinist-okd-in-europe-for-certain-type-of-melanoma\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386383\" data-ts=\"1535540918\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXPR\" target=\"_blank\">EXPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386383-expressplus-10-after-guidance-lift\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Express +10% after guidance lift</a></h4><ul> <li>Express (NYSE:<a href='https://seekingalpha.com/symbol/EXPR' title='Express, Inc.'>EXPR</a>) reports comparable sales increased 1.0% in <a href=\"https://seekingalpha.com/pr/17256008-express-inc-exceeds-second-quarter-2018-eps-guidance-introduces-third-quarter-guidance-raises\" target=\"_blank\">Q2</a> to top the consensus expectation for a dip of 0.1%.</li> <li>E-commerce sales soared 37% during the quarter.</li> <li>Gross margin landed at 28.4% of sales vs. 28.9% consensus and 27.8% a year ago. Operating margin rose 30 bps Y/Y to 0.5% of sales.</li>  <li>CEO update: \"Our launch of extended sizes is performing well and we are seeing success build from our expanded omni-channel capabilities, both of which are expected to deliver more benefit in the second half of 2018 and into 2019. Our financial position remains strong with $191 million in cash at quarter end and no debt. Under our $150 million share repurchase program, we have repurchased $49 million, or 6.1 million shares to date, underscoring our confidence in the business and commitment to driving shareholder value.\"</li> <li>Express hikes guidance to an outlook for Q3 EPS of $0.08 to $0.11 vs. $0.07 consensus and  2018 EPS of $0.43 to $0.49 vs. $0.42 consensus.</li> <li>Shares of Express are <font color='green'>up 10.11%</font> in premarket trading to $11.00.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386370-express-beats-0_04-beats-revenue\" target=\"_blank\">Express beats by $0.04, beats on revenue</a> (Aug. 29)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3386383\" data-linked=\"Express +10% after guidance lift\" data-tweet=\"$EXPR - Express +10% after guidance lift https://seekingalpha.com/news/3386383-expressplus-10-after-guidance-lift?source=tweet\" data-url=\"https://seekingalpha.com/news/3386383-expressplus-10-after-guidance-lift\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386382\" data-ts=\"1535540908\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MOV\" target=\"_blank\">MOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386382-movado-raised-fy2019-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Movado raised FY2019 guidance</a></h4><ul><li>Movado (NYSE:<a href='https://seekingalpha.com/symbol/MOV' title='Movado Group, Inc.'>MOV</a>) reports net sales rose 10.5%&nbsp;on a constant currency basis in <a href=\"https://seekingalpha.com/pr/17256005-movado-group-inc-announces-second-quarter-results\" target=\"_blank\">Q2</a>.</li><li>Adjusted gross margin rate leveraged 240 bps to 54%, primarily the result of changes in channel and product mix, favorable changes in foreign currency exchange rates and increased leverage on fixed costs due to increased sales.</li><li>Adjusted operating margin rate up 10 bps to 10%.</li><li>Inventory -3.1% Y/Y to $171.42M.</li><li>The Company repurchased 21.9K shares during the quarter.</li><li><b>FY2019 Guidance</b>: Net sales: $660M to $675M; Operating income: ~$75M to $77M; Tax rate: 22%; Net income: ~$58M to $59.7M; Diluted EPS: $2.45 to $2.55.</li><li>MOV&nbsp;<font color='green'>+3.44%</font>&nbsp;premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386368-movado-eps-line-beats-revenue\" target=\"_blank\">Movado EPS in-line, beats on revenue</a> (Aug. 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3386382\" data-linked=\"Movado raised FY2019 guidance\" data-tweet=\"$MOV - Movado raised FY2019 guidance https://seekingalpha.com/news/3386382-movado-raised-fy2019-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3386382-movado-raised-fy2019-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386380\" data-ts=\"1535540817\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHC\" target=\"_blank\">BHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386380-fda-accepts-bausch-healths-resubmitted-marketing-application-for-duobrii-lotion-for-plaque\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Bausch Health&#39;s resubmitted marketing application for Duobrii lotion for plaque psoriasis, action date February 15</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17256025-fda-accepts-resubmission-new-drug-application-duobrii-1-halobetasol-propionate-tazarotene\" target=\"_blank\">accepts for review </a>Bausch Health Companies (NYSE:<a href='https://seekingalpha.com/symbol/BHC' title='Bausch Health Companies Inc.'>BHC</a>) unit Ortho Dermatologics' refiled New Drug Application &#40;NDA&#41; seeking approval for DUOBRII (halobetasol propionate and tazarotene) for the topical treatment of plaque psoriasis. The agency's action date is February 15, 2019.</li><li>The company received a CRL in response to its first filing citing issues with the pharmacokinetic data.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3364534-fda-rejects-valeants-application-psoriasis-lotion-duobrii-shares-5-percent-premarket\" target=\"_blank\">FDA rejects Valeant's application for psoriasis lotion Duobrii; shares down 5% premarket</a> (June 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3386380\" data-linked=\"FDA accepts Bausch Health&#39;s resubmitted marketing application for Duobrii lotion for plaque psoriasis, action date February 15\" data-tweet=\"$BHC - FDA accepts Bausch Health&#39;s resubmitted marketing application for Duobrii lotion for plaque psoriasis, action date February 15 https://seekingalpha.com/news/3386380-fda-accepts-bausch-healths-resubmitted-marketing-application-for-duobrii-lotion-for-plaque?source=tweet\" data-url=\"https://seekingalpha.com/news/3386380-fda-accepts-bausch-healths-resubmitted-marketing-application-for-duobrii-lotion-for-plaque\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>51&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3386368\" data-ts=\"1535539594\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MOV\" target=\"_blank\">MOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3386368-movado-eps-in-line-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Movado EPS in-line, beats on revenue</a></h4><ul><li>Movado (NYSE:<a href='https://seekingalpha.com/symbol/MOV' title='Movado Group, Inc.'>MOV</a>): Q2 Non-GAAP EPS of $0.45 in-line; GAAP EPS of $0.39.</li><li>Revenue of $144.09M (+11.9% Y/Y) <font color='green'>beats by $6.59M</font>.</li><li>Shares <font color='green'>+3.44%</font> PM.</li><li><a href='https://seekingalpha.com/pr/17256005-movado-group-inc-announces-second-quarter-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3386368\" data-linked=\"Movado EPS in-line, beats on revenue\" data-tweet=\"$MOV - Movado EPS in-line, beats on revenue https://seekingalpha.com/news/3386368-movado-eps-in-line-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3386368-movado-eps-in-line-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:46 AM </div></div></li>","count":74,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}